



Final  
Program

3RD  
SYSTEMIC  
SCLEROSIS  
WORLD  
CONGRESS

FEBRUARY 6-8, 2014  
ROME, ITALY



Under the patronage of

## Committees

---

### Honorary Presidents

C Black, S Jablonska,  
F Wollheim, T Medsger

### Steering Committee

DE Furst, M Matucci-Cerinic, A Tyndall,  
U Mueller-Ladner, L Guillevin, K Takehara,  
J Seibold and the following Chairpersons:

1. Chairpersons of the Abstract Committee:  
**O Distler, P Sampaio Barros**
2. Chairpersons of the Clinical Committee:  
**Y Allamore, D Khanna**
3. Chairpersons of the Basic Committee:  
**J Varga, J Distler**
4. Chairperson of the Workshops:  
**P Clements**
5. Liaison officer with the Scleroderma Workshop:  
**C Denton, R Lafyatis**
6. Chairpersons of the Mentoring Programme:  
**L Czirjak, M Mayes**

### Scientific Committee

D Abraham, M Baron, P Carreira, M Cutolo,  
N Damjanov, F Del Galdo, J Distler, A Gabrielli, S Gay,  
R Giacomelli, E Hachulla, A Herrick, M Inanc,  
B Kahaleh, R Knobler, O Kowal-Bielecka, T Krieg,  
M Kuwana, MT Li, P Merkel, J Pope, S Rednic,  
G Riemekasten, S Sato, J Scali, Y Shoenfeld, R Silver,  
V Steen, R Simms, M Trojanowska, G Valentini, F van  
den Hoogen, J van Laar, U Walker, A Wells, F Wigley

### FESCA Board

A Tyrrell Kennedy, *President*  
B Garay-Toth, *Vice-President*  
D Demetriou-Charalambous, *Treasurer*  
Alexandra Portales, *Secretary*  
C Van den Bosch, *Legal Advisor*

# SCIENTIFIC PROGRAM



## THURSDAY, FEBRUARY 6

13:30–16:45 **Pre–Meeting workshops**

See program at page 9

17:00–18:00 **Satellite Symposia**

See program at page 12

18:15 **Welcome from the World Scleroderma Foundation** LEPTIS MAGNA ROOM

18:30 **Welcome from the Patron of the World Scleroderma Foundation** LEPTIS MAGNA ROOM  
The impact of scleroderma on a creative genius  
**A. Klee (CH)**

18.45-19.00 **Welcome from the Patients' Representative** LEPTIS MAGNA ROOM  
The Patients' Perspective  
**A Kennedy (IRL), President of FESCA**

19:00-19:40 **Opening Lectures** LEPTIS MAGNA ROOM  
**Two-years in Review-What's new since Madrid: the Cutting Edge**  
Chairpersons: **C Black (UK), F Wollheim (S)**

19:00 The clinical overview  
**M Matucci-Cerinic (I)**

19:20 The basic and translational I overview  
**J Varga (USA)**

19:40 **Rome Video**

20:00 **Light welcome cocktail**

THURSDAY, FEBRUARY 6  
FRIDAY, FEBRUARY 7

## FRIDAY, FEBRUARY 7

FRIDAY, FEBRUARY 7

08:00–09:20 **Session 1** LEPTIS MAGNA ROOM**Management and assessment  
of newly diagnosed SSc****Chairpersons: J van Laar (UK), N Damjanov (SR)**

- 08:00 What to do for a patient with newly diagnosed SSc
- How to assess a patient with new onset of possible systemic sclerosis
  - What are the standard of care tests in early SSc patient
  - What are the baseline factors of poor prognosis in very early and early SSc

**P Clements (USA)****Chairpersons: F Van den Hoogen (NL),  
S Johnson (CAN)**

08:20 NEW EULAR/ACR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN CLINICAL PRACTICE  
**O Distler et al (CH)**

08:30 2013 CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS AN AMERICAN COLLEGE OF RHEUMATOLOGY/EUROPEAN LEAGUE AGAINST RHEUMATISM COLLABORATIVE INITIATIVE.  
**J Pope et al (CAN)**

08:40 PERFORMANCE OF THE OLD 1980 ACR AND THE NEW ACR-EULAR SYSTEMIC SCLEROSIS (SSC) CLASSIFICATION CRITERIA IN PATIENTS WITH LIMITED CUTANEOUS SSC  
**P Carreira et al (E)**

08:50 EARLY ACCRUAL OF ORGAN DAMAGE IN SCLERODERMA: RATIONALE FOR DERIVATION AND VALIDATION OF A DISEASE DAMAGE INDEX IN SYSTEMIC SCLEROSIS  
**T Tay et al (AUS)**

09:00 PERFORMANCE OF THE 2013 ACR/EULAR CLASSIFICATION CRITERIA FOR SYSTEMIC SCLEROSIS IN A SINGLE CENTER SETTING  
**R Dobrota et al (R)**

09:10 SSC INTRINSIC SUBSET CLASSIFICATION IN PATIENTS THAT DEMONSTRATE CLINICAL IMPROVEMENT DURING TREATMENT  
**M Whitfield et al (USA)**

09:20–10:10 **Session 2** LEPTIS MAGNA ROOM  
**Miscellaneous and differential diagnosis of SSc**  
**Chairpersons: U Walker (CH), R Silver (USA)**

09:20 How to differentiate SSc from scleroderma-like disorder?

- Criteria for very early and early diagnosis of SSc
- Differential diagnoses to be presented including IgG4 syndromes, Shulman, nephrogenic fibrosis, borreliosis

**A Tyndall (CH)**

09:40 GENDER EFFECTS ON SYSTEMIC SCLEROSIS PHENOTYPE: A LONGITUDINAL EUSTAR STUDY BASED ON MORE THAN 10 000 PATIENTS  
**M Elhai et al (F)**

09:50 EPIDEMIOLOGY OF CANCER IN SYSTEMIC SCLEROSIS. SYSTEMATIC REVIEW AND META-ANALYSIS OF CANCER INCIDENCE, PREDICTORS AND MORTALITY  
**S Johnson et al (CAN)**

10:00 JOINT AND TENDON INVOLVEMENT PREDICT SEVERE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: A EUSTAR PROSPECTIVE STUDY  
**J Avouac et al (F)**

*10:10–10:30 COFFEE BREAK*

10:30–11:00 **Session 3** **LEPTIS MAGNA ROOM**  
**The great debate**  
**Chairpersons: R Giacomelli (I), B Maurer (CH)**

The place of Corticosteroids in SSc  
**T Medsger (USA), J Seibold (USA)**

11:00–12:00 **Poster tours**  
**Clinical**

Poster tour 1: Raynaud & Ulcers - **V Ricciari (I)**  
 PS01 to PS06

Poster tour 2: Raynaud & Ulcers - **E Rosato (I)**  
 PS07 to PS12

Poster tour 3: Pulmonary / Interstitial Lung  
 Disease - **I H Tarner (D)**  
 PS13 to PS19

Poster tour 4: Pulmonary Arterial Hypertension  
**D Launay (F)**  
 PS20 to PS27

Poster tour 5: Cardiac - **A Vacca (I)**  
 PS28 to PS34

Poster tour 6: Outcomes, quality of life,  
 psychological & social - **P Carreira (E)**  
 PS35 to PS41

Poster tour 7: Imaging - **F Cozzi (I)**  
 PS42 to PS48

Poster tour 8: Therapy/Miscellaneous - **A Sulli (I)**  
 PS49 to PS55

Poster tour 9: Musculoskeletal system  
 & rehabilitation - **P Ostojic (SRB)**  
 PS56 to PS61

Poster tour 10: Upper and Lower Gastrointestinal/  
 nutrition - **T Minier (H)**  
 PS62 to PS68

Poster tour 11: Pregnancy & sexual problems  
**L Saketkoo (USA)**  
 PS69 to PS73

Poster tour 12: Therapy - **S Bellando-Randone (I)**  
 PS74 to PS82

**Basic**  
 Poster tour 13: Pathogenesis - **M Manetti (I)**  
 PS83 to PS94

Poster tour 14: Pathogenesis - **GL Moroncini (I)**  
 PS95 to PS102

Poster tour 15: Pathogenesis - **S Assassi (USA)**  
 PS103 to PS111

12:00–13:30 **Satellite Symposia**  
 See program at page 11

13:30–14:30 **Working lunch** **LEVEL –2**

14:30–15:30 **Satellite Symposia**  
 See program at page 11

15:30–16:40 **Concurrent Sessions**

15:30–16:30 **Concurrent Session 4** **LEPTIS MAGNA ROOM**  
**An integrated approach to**  
**gastro–intestinal involvement**  
**Chairpersons: A Herrick (UK), T Frech (USA)**

15:30 GI: How to evaluate, diagnose and treat upper and  
 lower GI involvement  
**U Mueller–Ladner (D)**

- 15:50 New therapeutic approaches  
**C Murray (UK)**
- 16:10 MORTALITY, RECURRENCE, AND HOSPITAL COURSE OF PATIENTS WITH SYSTEMIC SCLEROSIS RELATED ACUTE INTESTINAL PSEUDO-OBSTRUCTION  
**C Derk et al (USA)**
- 16:20 PREVALENCE, CORRELATES AND OUTCOMES OF GASTRIC ANTRAL VASCULAR ECTASIA IN SYSTEMIC SCLEROSIS: A EUSTAR CASE-CONTROL STUDY  
**E Ghrenassia et al (F)**
- 15:30-16:40 **Concurrent Session 5** MASSALIA ROOM  
**Links to inflammation, immunity and vascular disease**  
**Chairpersons: J Distler (D), D Abraham (UK)**
- 15:30 Immunological mechanisms of fibrosis  
**T Wynn (USA)**
- 15:50 PIGMENT EPITHELIUM DERIVED FACTOR SECRETED BY SSC FIBROBLASTS INHIBITS ANGIO AND VASCULOGENESIS IN VITRO  
**V Liakouli et al (I)**
- 16:00 SCLERODERMA DERMAL FIBROBLASTS OVEREXPRESS VASCULAR ENDOTHELIAL GROWTH FACTOR DUE TO AUTOCRINE TRANSFORMING GROWTH FACTOR BETA SIGNALING  
**I Kajihara et al (JPN)**
- 16:10 IL 6 TRANS-SIGNALING AND CCL2 CO-REGULATE FIBROBLAST DEPENDENT TRANS-ENDOTHELIAL MIGRATION OF MONONUCLEAR CELLS AND FIBROTIC RESPONSE IN SCLERODERMA  
**R Alade et al (UK)**
- 16:20 THE GLOBAL MICRORNA PROFILE OF SKIN IN SYSTEMIC SCLEROSIS  
**G Salazar et al (USA)**
- 16:30 THE PRESENCE OF A COLD TEMPERATURE SENSOR IN THE VASCULAR ENDOTHELIUM: ENHANCED EXPRESSION IN SSC SKIN AND ENDOTHELIAL CELLS DYSFUNCTION AFTER ACTIVATION  
**B Kahaleh et al (USA)**
- 16:40-16:55 *COFFEE BREAK*
- 16:55-18:15 **Concurrent Sessions**
- 16:55-17:25 **Concurrent Session 6** LEPTIS MAGNA ROOM  
**Biologics and novel therapies in SSc**  
**Chairpersons: R Simms (USA), C Beyer (D)**
- 16:55 Use of biologics in SSc-indications and future perspective  
- An update on the use of biologics in SSc  
- Benefit/risk ratio of the main molecules  
- Upcoming trials  
**Y Allanore (F)**
- 17:25-17:55 **Concurrent Session 7** LEPTIS MAGNA ROOM  
**Treatment and DMARDs in SSc**  
**Chairpersons: P Sampaio Barros (BRA), M Kuwana (JPN)**
- 17:25 How to treat rapidly progressive SSc  
**C Denton (UK)**
- 16:55-18:15 **Concurrent Session 8** MASSALIA ROOM  
**Mechanism of fibrosis**  
**Chairpersons: A Gabrielli (I), R Lafyatis (USA)**
- 16:55 Biomechanical Signaling of Myofibroblast Activation  
**V Thannickal (USA)**
- 17:15 SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) REGULATES TRANSFORMING GROWTH FACTOR-BETA INDUCED FIBROSIS IN SYSTEMIC SCLEROSIS  
**B Sumova et al (D)**

17:25 INVESTIGATING THE ROLE OF MYOCARDIN RELATED TRANSCRIPTION FACTOR (MRTF) IN SYSTEMIC SCLEROSIS  
**X Shiwen et al (UK)**

Approach to Ulcer Therapy  
**M Vonk (NL) & S Guiducci (I)**

HAMA ROOM

17:35 EPHRIN B2 IS OVEREXPRESSED IN HUMAN SCLERODERMA SKIN AND MEDIATES FIBROBLAST TO MYOFIBROBLAST DIFFERENTIATION, AND INDUCES FIBROSIS IN MICE  
**M Kapoor et al (CAN)**

Approach to Therapy of Tendon & Joint Inflammation  
**M Mayes (USA)**

MILETO ROOM

17:45 EXPERIMENTAL RENAL INJURY IN A TGF $\beta$  DEPENDENT MOUSE MODEL OF SCLERODERMA  
**E Derrett-Smith et al (UK)**

09:00–09:40 **Session 10**

LEPTIS MAGNA ROOM

**Cardiovascular involvement**Chairpersons: **M Inanc (TR), A Vacca (I)**

17:55 DIRECT THROMBIN INHIBITOR DABIGATRAN ETEXILATE PROTECTS ALVEOLAR EPITHELIAL CELLS FROM APOPTOSIS IN A BLEOMYCIN MODEL OF SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE  
**G Bogatkevich et al (USA)**

09:00 Conduction and Rhythm defects in scleroderma  
**C Meune (F)**

09:20 IMPROVEMENT OF DIGITAL ULCERATIVE DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS IS ASSOCIATED WITH BETTER FUNCTIONAL PROGNOSIS  
**L Mouthon et al (F)**

18:05 STIMULATION OF THE SOLUBLE GUANYLATE CYCLASE (SGC) INHIBITS DERMAL FIBROSIS BY BLOCKING NON-CANONICAL TGF- $\beta$ -SIGNALING  
**C Beyer et al (D)**

09:30 PREDICTION OF CARDIAC AND VASCULAR EVENTS IN SYSTEMIC SCLEROSIS: INPUT FROM ENDOTHELIN -1 TYPE A RECEPTOR ANTIBODIES  
**J Avouac et al (F)**

09:40–10:30 **Session 11**

LEPTIS MAGNA ROOM

**Interstitial lung disease**Chairpersons: **B Kahaleh (USA), O Kowal Bielecka (PI)**

## SATURDAY, FEBRUARY 8

08:00–09:00 **Session 9**  
**Meet the Professors session**  
See information at page: 42

Approach to SSc-Related Cardiac Disease  
**L Czirjak (H) & Y Allanore (F)**

CESAREA ROOM

Approach to Kidney Management  
**L Guillevin (F) & C Denton (UK)**

EFESO ROOM

09:40 SSc-ILD: Who to treat and how to treat?  
– Discuss natural history and disease progression in ILD  
– How to identify patients who require immuno suppressive therapy  
– Efficient drugs and predictors of response  
**D. Khanna (USA)**

- 10:00 PROGRESSIVE DETERIORATION OF PATIENTS WITH SCLERODERMA WITH PULMONARY INVOLVEMENT: 11-YEAR OUTCOMES FROM THE SCLERODERMA LUNG STUDY (SLS1)  
**K Sullivan et al (USA)**
- 10:10 SURVIVAL AFTER LUNG TRANSPLANTATION IN SYSTEMIC SCLEROSIS. A SYSTEMATIC REVIEW.  
**S Johnson et al (CAN)**
- 10:20 GENETIC MARKERS OF SUSCEPTIBILITY AND INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS PATIENTS: AN IMMUNOCHIP STUDY  
**L Bossini-Castillo et al (E)**
- 10:30-10:45 *COFFEE BREAK*
- 10:45-11:55 **Session 12** **LEPTIS MAGNA ROOM**  
**Pulmonary Arterial Hypertension**  
Chairpersons: **V Steen (USA), E Hachulla (F)**
- 10:45 PAH: How to make the right diagnosis at the right time  
– Risk factors and predictors of PAH  
– Criteria guiding the clinician to refer the patient for catheterisation  
– How to interpret catheterisation  
**O Distler (CH)**  
  
Chairpersons: **M Hinchcliff (USA), L Chung (USA)**
- 11:05 CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY HYPERTENSION AND A PULMONARY CAPILLARY WEDGE PRESSURE >15 IN THE PHAROS REGISTRY  
**L Saketkoo et al (USA)**
- 11:15 RECOMMENDATIONS FOR SCREENING AND DETECTION OF CONNECTIVE -TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION  
**D Khanna et al (USA)**
- 11:25 A COMPARISON OF THE PREDICTIVE ACCURACY OF THREE SCREENING MODELS (DETECT V. ESC/ERS V. ASIG) FOR PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS  
**Y J Hao et al (AUS)**
- 11:35 CLINICAL SUBTYPE AND AUTOANTIBODIES BOTH HELP PREDICT PULMONARY ARTERIAL HYPERTENSION BUT AUTOANTIBODIES ARE STRONGER PREDICTORS OF DEVELOPING SECONDARY PULMONARY HYPERTENSION  
**R Domsic et al (USA)**
- 11:45 PROGNOSTIC VALUE OF NT-PROBNP IN SYSTEMIC SCLEROSIS PATIENTS WITHOUT PULMONARY HYPERTENSION  
**M Antivalle et al (I)**
- 11:55-12.10 **Special Lecture** **LEPTIS MAGNA ROOM**  
Chairpersons: **F Del Galdo (UK), G Riemekasten (D)**  
  
DeSSciper, a jump in the future!  
**U Mueller-Ladner (D)**
- 12:10-12.30 **Summary of the congress** **LEPTIS MAGNA ROOM**  
Chairperson: **L Guillevin (F)**  
  
Highlites of the World Scleroderma Congress, 2014  
**D Furst (USA)**
- 12:30-13:00 **Closing Ceremony** **LEPTIS MAGNA ROOM**



# WORKSHOP PROGRAM

Workshops will be held on **Thursday, February 6.**

90 minutes workshops will be repeated twice,  
180 minutes workshops all at once.

Reservation is requested. Left places can be booked at  
the “New Registration” desk at the registration desk.

**Coordinator: Phil Clements (USA)**

## **90 minutes workshops**

The following 90 minutes workshops will be held twice:

First time: from 13:30 to 15:00

Second time: from 15:15 to 16:45

A coffee break will be served from 15:00 to 15:15  
between the first and second time of the workshops

### **Skin Scoring**

SPALATO ROOM

Convenors: D Furst (USA), L Czirjak (H)

### **How to do skin biopsy and biologic storage**

MILETO ROOM

Convenors: O Distler (CH), C Beyer (D)

### **HRCT fibrosis scoring**

TREVIRI ROOM

Convenor: A Wells (UK)

### **Autoantibodies**

HAMA ROOM

Convenor: T Medsger (USA)

The following workshop will be held only from 15:15 to 16:45

**Clinical features and treatment of Juvenile Systemic Sclerosis**

MERIDA ROOM

**Convenors: I Foeldari (D), F Zulian (I)**

15.15 Which child with a Raynaud Phenomenon should we follow closely?

**C Pain (UK)**

15.35 Classification and monitoring of juvenile systemic sclerosis

**F Zulian (I)**

16.00 Is juvenile systemic sclerosis a different disease from the adult onset disease?

Clinical and outcome data

**I Foeldvari (D)**

16.30 Discussion

**180 minutes workshops**

The following 180 minutes workshops will be held from 13:30 to 16:45.

**Nailfold Capillaroscopy**

POLA ROOM

**Convenor: M Cutolo (I)**

13:30 Introduction of the workshop

**M Cutolo (I)**

13:35 Raynaud's phenomenon: A clinical symptom revisited

**A L Herrick (UK)**

14:00 From Raynaud's phenomenon up to systemic sclerosis: understanding the role of capillaroscopy

**M Cutolo (I)**

14:20 Selecting the most appropriate capillaroscopic device: pros and cons

**A Sulli (I)**

14:35 How to distinguish the pathological capillaroscopic patterns from a normal pattern

**V Smith (B)**

*15:05-15:20 COFFEE BREAK*

15:20 How to quantitatively score the qualitative capillaroscopic patterns in systemic sclerosis

**A Sulli (I)**

15:35 The prognostic role of capillaroscopy for digital ulcers: from the DTD index to the CAPSTUDY model and therapeutical effects

**M Cutolo (I)**

16:05 Introduction and presentation patients for practical session

**V Ricciari (I)**

16:15 Practical session with patients

**All tutors**

**Ultrasound in scleroderma: applications and challenges**

ALCANTARA ROOM

**Convenor: E Naredo (E)**

**Joint inflamamtion: synovitis and tenosynovitis**

13:30 How to detect?

**I Möller (E)**

13:50 How to score?

**E Naredo (E)**

14:10 Workshop on joints and tendons

*15:00-15:15 COFFEE BREAK*

**Skin**

15:15 B-mode and Doppler assessment  
**F Porta (I)**

15:35 US elastography  
**A Iagnocco (I)**

15:55 Workshop on skin

**Localized scleroderma –  
diagnostic and therapeutic challenges**

EFESO ROOM

Convenors: **R Knobler (A), T Krieg (D)**

13:30 Diagnosis and Classification of localized  
scleroderma and related diseases  
**P Moinzadeh (D)**

13:40 Discussion

13:50 Systemic involvement in localized scleroderma?  
Discussion round (Introduction and Chair)  
**I Foedvari (D), F Zulian (I)**

14:15 Pseudoscleroderma – diagnostic pitfalls  
**C Orteu (UK)**

14:25 Are there overlaps between localized and  
systemic scleroderma?  
**A Jalili (A)**

14:35 Discussion

*14:50–15:05 COFFEE BREAK*

15:05 Potential Pathomechanisms  
**L Mouthon (F)**

15:15 Role of Borrelia, other infections and triggers.  
Discussion round (Introduction and Chair)  
**R Müllegger (A)**

15:40 UV associated and topical treatment  
**U Just (A), R Knobler (A)**

15:50 Cyclosporine–Therapy in localized scleroderma  
**K Takehara (J)**

16:00 Other systemic immunosuppressive therapies  
and novel approaches  
**A Kreuter (D)**

16:10 Discussion

16:20 Development of guidelines.  
Discussion round (Introduction and Chair)  
**N Hunzelmann (D)**

# SATELLITE SYMPOSIA



## FIDIA SATELLITE SYMPOSIUM

---

LEPTIS MAGNA ROOM

**Thursday, February 6**

17:00–18:00

### **Management of sclerodermic digital ulcers: a novel approach**

**Chairperson: V Ricciari (I)**

17:00 Management of cutaneous ulcers  
in sclerodermic patients  
**S Guiducci (I)**

17:30 Hyaluronic acid as a key factor in the wound  
healing process of sclerodermic cutaneous ulcers  
**A Passi (I)**

## ACTELION SATELLITE SYMPOSIUM

---

LEPTIS MAGNA ROOM

**Friday, February 7**

12:00–13:30

### **Tackling the organ manifestations of systemic sclerosis**

**Chairpersons: Y Allanore (F), C Denton (UK)**

12:00 Introduction  
**C Denton (UK)**

12:10 The case of Steffi (Part 1) –  
Managing the early stages of SSc  
**U Mueller–Ladner (D)**

12:20 Focusing on early detection of SSc and  
addressing initial manifestations  
**M Matucci–Cerinic (I)**

12:40 The case of Steffi (Part 2) – The story continues  
**U Mueller–Ladner (D)**

## ACTELION SATELLITE SYMPOSIUM

continue

- 12:50 How to DETECT and manage pulmonary arterial hypertension in SSc  
**D Khanna (USA)**
- 13:10 Panel discussion  
**All**
- 13:25 Closing remarks  
**Y Allanore (F)**

## GLAXOSMITHKLINE SATELLITE SYMPOSIUM

LEPTIS MAGNA ROOM

**Friday, February 7**

14:30–15:30

**Challenges in CTD-PAH management - New real life data from VOLT registry**

**Chairperson: M Matucci-Cerinic (I)**

- 14:30 Pulmonary hypertension and interstitial fibrosis in CTD patients  
**C Denton (UK)**
- 14:50 Prognostic factors in PAH associated to CTD  
**E Hachulla (F)**
- 15:10 Pulmonary Arterial Hypertension: Results of the VOLT study, with an emphasis on PAH associated with Connective Tissue Disease  
**A Peacock (UK)**

# PATIENT PROGRAM



## THURSDAY, FEBRUARY 6

THURSDAY, FEBRUARY 6  
FRIDAY, FEBRUARY 7

17:00–18:00 **Round-table** **TARRAGONA ROOM**

### **Networking Meeting for Leaders of Patient Groups**

All patient association leaders welcome to this informal discussion to exchange ideas. No powerpoint presentations. Pre-registration by email is preferred. English will be the language of the meeting; no translation will be provided this day.

18:15–20:00 **Opening Ceremony of both Medical and Patient congresses**

*The Medical Programme of lectures is conducted separately from the Patient Programme. The Patient Programme in Keynote Room Orange will be translated simultaneously into Italian, French, and Spanish. Interactive sessions consist of presentations and discussions.*

## FRIDAY, FEBRUARY 7

**ORANGE ROOM**

09:00–09:10 **FESCA aisbl. Welcome**  
**Ann Kennedy (IRL)**

09:10 Why did I get scleroderma and will I be cured?  
**Jaap van Laar (UK)**

09:30–10:30 **Breathing**  
**Chairs: Beata Garay-Toth (H)  
& Ulf Mueller-Ladner (D)**

09:30 Why is breathing so difficult?  
**Oliver Distler (D)**

09:50 The patient perspective on lung problems  
**Kim Fligelstone (UK)**

10:05 Questions - Interactive session

10:30–11:00 **COFFEE BREAK**

11:00–11:45 **Nutrition and the Gut**  
**Chairs: Nadine Paciotti (CH)  
& Dinesh Khanna (USA)**

11:00 What can I do to help digestion processes?  
**Janet Pope (CAN)**

11:20 Tips for people with GI problems  
**Susie Hoare (UK)**

11:35 Questions

11:45–12:30 **Sexuality and Pregnancy**  
**Chairs: Despo Charalambous–Demetriou (CYP)**  
**& Gabi Riemekasten (D)**

11:45 Sexuality and Pregnancy in SSc  
**Angela Tincani (I)**

12:05 How I had a baby  
**Johanna Berglind (S)**  
**& Jessica Thonen–Velthuisen (NL)**

12:25 Questions – Interactive session

11:45–12:30 **Concurrent session** **ALCANTARA ROOM**  
**Juvenile Scleroderma**  
**Chair: Kim Fligelstone (UK)**  
 Panel: Ivan Foeldvari (D), Clare Pain (UK)  
 & Linda Schraven (NL).  
 This is an interactive session for parents and  
 young people with scleroderma to ask questions.  
 In English. **No translation will be provided.**

11:45–12:30 **Concurrent session** **TREVIRI ROOM**  
**For Men Only**  
**Chair: Kent Krarup (DK)**  
 Panel: Richard Silver (USA), Richard Dodds (UK)  
 & Joep Welling (NL).  
 This is an interactive session for men with  
 scleroderma to ask questions of the panel.  
 No women. In English. **No translation will be  
 provided.**

12:30–14:00 LUNCH

14:00–15:00 **Systemic Treatments**  
**Chairs: Ann Kennedy (CH)**  
**& Jaap van Laar (UK)**

14:00 Transplants of different kinds—are they for me?  
**Alan Tyndall (CH)**

14:20 A patient perspective on transplants  
**Gabrielle Verzi (I)**

14:30 My story, my transplant  
**Jessica Thonen–Velthuisen (NL)**

14:40 Questions – Interactive session with the panel

14:00–15:00 **Concurrent session** **SPALATO ROOM**  
**Breathing Exercises**  
 Physiotherapist Jadranka Brozd gives an  
 interactive workshop on how to improve breathing.

15:00–16:00 **Exercise and Therapies**  
**Chairs: Alexandra Portales (E)**  
**& Tony Redmond (UK)**

15:00 Hand and face exercises  
**Paul Briffa (UK)**

15:15 Dentistry in SSc  
**Roberto Rozza (I)**

15:30 Useful equipment and tips  
**Annelise Roennow (DK)**  
 followed by questions to panel

## SATURDAY, FEBRUARY 8

09:00–09:15 **New EULAR–ACR classification of SSc**  
**Frank van den Hoogen (NL)**

09:15–10:00 **Concurrent sessions**  
**New Treatments in Scleroderma**

In English: **Chris Denton (UK)** **ORANGE ROOM**

In French, no powerpoints: **ALCANTARA ROOM**  
**Yannick Allanore (F)**

In Spanish, no powerpoints: **SPALATO ROOM**  
**Patricia Carreira (E)**

In Italian, no powerpoints: **MERIDA ROOM**  
**Marco Matucci–Ceric (I)**

10:00–10:45 **Ulcers and the Hands**  
**Chairs: Grazia Tassini (I) & László Czirják (H)**

10:00 What can be done for my digital ulcers?  
**Marco Matucci–Ceric (I)**

10:20 Taking care of your ulcers  
**Barbara Gemmell (AUS)**

10:35 Questions to the Panel

10:00–10:45 **Concurrent session** **SPALATO ROOM**  
**Workshop in methods of facial camouflage**

10:00 Lasers & corrective make-up for telangiectasia & more  
**Antoine Fauconneau (F)**

10:20 Questions and Answers  
**Antoine Fauconneau (F)**  
**& Marie–Sylvie Doutre (F)**

10:45 Small Group Workshops continue in this room until 12.00.

*10:45–11:15 COFFEE BREAK*

11:15–12:00 **What are your Concerns? Ask the Professor**  
**Chairs: Ann Kennedy (IRL) & Joep Welling (NL)**  
**Panel: Chris Denton (UK) & Janet Pope (CAN)**  
 Interactive session. Written questions in advance would be appreciated.

12:00–13:30 **Coping with Scleroderma**  
**Chairs: Annelise Roennow (DK)**  
**& Els van den Ende (NL)**

12:00 Carers and Family members  
**Robyn Simms (USA)**

12:10 Coping with the emotional aspects of SSc  
**Brett Thombs (CAN)**

12:25 Fatigue and how to deal with it  
**Janet Poole (USA)**

12:45 Questions for the panel on coping with SSc

13:00 **Closure of Medical and Patient Congresses**

14:00 **FESCA aisbl AGM** **TREVIRI ROOM**  
 for official representatives of each member organisation



# POSTER SESSION



- PS01** **DECREASE OF BRACHIAL ARTERY ENDOTHELIAL-DEPENDENT FLOW-MEDIATED DILATION CHARACTERIZES VERY EARLY SYSTEMIC SCLEROSIS (VEDOSS) PATIENTS**  
S.L. Bosello, A. Di Giorgio, F. Foti, G. De Luca, M. Bocci, F. Parisi, A. Capacci, G. Berardi, M. Rucco, M. Correrà, G. Canestrari, A. Santoliquido, G. Ferraccioli
- PS02** **DIAGNOSTIC STANDARDS FOR CHILDREN WITH RAYNAUD'S PHENOMENON**  
T. Constantin, C. Pain, N. Toplak, M. Moll, I. Konert, D. Piotto, N. Aktay, D. Nemcova, P. Hoeger, M. Cutolo, V. Smith, I. Foeldvari
- PS03** **ANTI-ENDOTHELIAL CELL ANTIBODIES AS BIOMARKER OF SEVERE VASCULAR MANIFESTATIONS IN SYSTEMIC SCLEROSIS**  
C. Muñoz Vahos, C. Goldenstein-Schainberg, V.S. Viana, S. Carrasco, E.P. Leon, E. Bonfa, G. Vasquez, P.D. Sampaio-Barros
- PS04** **NAILFOLD VIDEOCAPILLAROSCOPY AND OTHER PREDICTIVE FACTORS ASSOCIATED WITH NEW DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: RESULTS FROM THE CAP STUDY**  
M. Cutolo, A. Herrick, O. Distler, M. Becker, E. Beltran, P. Carpentier, C. Ferri, M. Inanc, P. Vlachoyiannopoulos, H. Chadha-Boreham, E. Cottreal, T. Pfister, D. Rosenberg, J. Torres, V. Smith
- PS05** **MICRORNA-34A AND MICRORNA-155 IN RAYNAUD PHENOMENON: POSSIBLE EPIGENETIC BIOMARKERS OF ENDOTHELIAL DYSFUNCTION IN SYSTEMIC SCLEROSIS**  
S. Alivernini, S. Bosello, G. De Luca, M. Bocci, S. Canestri, F. Foti, C. Di Mario, B. Tulusso, G. Ferraccioli
- PS06** **PHOSPHODIESTERASE-5 INHIBITORS FOR THE TREATMENT OF SECONDARY RAYNAUD'S PHENOMENON: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS**  
M. Roustit, S. Blaise, Y. Allanore, P.H. Carpentier, E. Caglayan, J.-L. Cracowski
- PS07** **CHARACTERIZATION OF LOWER LIMB CUTANEOUS ULCERS IN SYSTEMIC SCLEROSIS: THE ANALYSIS OF 554 LESIONS**  
J. Blagojevic, G. Piemonte, L. Benelli, F. Braschi, G. Fiori, G. Carnesecchi, S. Guiducci, G. Lepri, S. Bellando Randone, M. Maticci Cerinic
- PS08** **CLINICAL FEATURES AND CHARACTERISTICS OF PATIENTS WITH DIGITAL ULCERS (DU) IN SYSTEMIC SCLEROSIS (SSC) IN THE CZECH REPUBLIC: DATA FROM THE DUO REGISTRY**  
R. Becvar, M. Maticci-Cerinic, C.P. Denton, B. Schwierin, C. Du Roure, D. Rosenberg, M. Scott, T. Krieg, L. Guillevin
- PS09** **PREDICTORS OF DIGITAL ULCERS IN PATIENTS WITH SECONDARY RAYNAUD PHENOMENON: CORRELATION BETWEEN CLINICAL AND HEMODYNAMIC FEATURES, CAPILLAROSCOPY, ENDOTHELIUM DYSFUNCTION AND ANGIOGENESIS BIOMARKERS**  
I. Silva, I. Almeida, C. Vasconcelos

- PS10** IONTOPHORESIS OF TREPROSTINIL AS A TREATMENT OF ISCHEMIC DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A PROOF-OF-CONCEPT STUDY  
M. Roustit, F. Gaillard-Bigot, S. Blaise, F. Stanke-Labesque, C. Cracowski, C. Seinturier, J.-F. Jourdil, B. Imbert, P.H. Carpentier, J.-L. Cracowski
- PS11** EVALUATION OF THE EFFICACY OF SILDENAFIL ON TIME TO HEALING IN PATIENTS WITH SCLERODERMA AND ISCHAEMIC DIGITAL ULCERS (SEDUCE): PATIENTS' CHARACTERISTICS AT BASELINE  
E. Hachulla, P. Carpentier, C. Agard, E. Chatelus, P. Jegou, L. Mouthon, V. Queyrel, A.L. Fauchais, U. Pasturel-Michon, P.Y. Hatron, P. Clerson
- PS12** LASER SPECKLE CONTRAST ANALYSIS TECHNIQUE FOR THE FOLLOW-UP OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS PATIENTS  
B. Ruaro, A. Sulli, T. Cannavale, E. Bernero, M.A. Cimmino, B. Seriole, M. Cutolo
- PS13** PULMONARY FIBROSIS INDUCED BY BLEOMYCIN IS DRIVEN BY HIGH COLLAGEN V AND TGF <BETA> SYNTHESIS  
V. Martins, D.B. Lopes, M. Antunes, A.P.P. Velosa, W.R. Teodoro, E.R. Parra, V.L. Capelozzi
- PS14** DISTORTED LUNG FRAMEWORK IS RELATED TO IL-17+ CELLS IMMUNOEXPRESSION IN SYSTEMIC SCLEROSIS  
A. Pereira Velosa, MA. Paiva, PC. Andrade, MP. Rangel, RB. Christmann, EM. Eher, SM. Ferezlian, ER. Parra, WR. Teodoro, VL. Capelozzi
- PS15** DOES MYCOPHENOLATE MOFETIL (MMF) HAVE AN EFFECT ON PULMONARY HEMODYNAMICS? OBSERVATIONS FROM THE PULMONARY HYPERTENSION ASSESSMENT AND RECOGNITION OF OUTCOMES IN SCLERODERMA (PHAROS) COHORT  
L. Saketkoo, M. Lammi, J. Gordon, P. Lauto, V. Steen
- PS16** DEVELOPMENT OF A COMPOSITE OUTCOME MEASURE FOR SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE  
E. Volkmann, N. Li, D. Tashkin, D. Furst, R. Elashoff
- PS17** LUNG ULTRASOUND FOR DETECTING INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS  
R. López Martínez, R. Hassan, L. Lubertino, V. Cosentino, M. Barth, C. Saenz, M. Binda, S. Montoya, E. Kerzberg
- PS18** INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: CLINICAL PRESENTATION AND COURSE DIFFERENCES BETWEEN PM/SCL AND SCL-70 ANTIBODIES  
A. Guillen-Del Castillo, C.P. Simeon-Aznar, V. Fonollosa-Pla, S. Alonso-Vila, A. Fernandez-Codina, A. Selva-O'Callaghan, M. Vilardell-Tarres
- PS19** LONG TERM FOLLOW-UP AFTER INTRAVENOUS CYCLOPHOSPHAMIDE PULSE THERAPY FOR SCLERODERMA INTERSTITIAL LUNG DISEASE: RESULTS OF A SINGLE CENTER EXPERIENCE  
A. Balbir-gurman, M. Yigla, L. Guralnik, A. Rozin, K. Toledano, D. Markovits, E. Hardak, A. Solomonov, R. Beshara, A. Dagan, M. Nahir, Y. Braun-Moscovici
- PS20** PULMONARY ARTERIAL HYPERTENSION (PAH) IN A CONTEMPORARY DRUG REGISTRY: RESULTS OF THE VOLT STUDY, WITH AN EMPHASIS ON PAH ASSOCIATED WITH CONNECTIVE TISSUE DISEASE (CTD)  
J.L. Vachiéry, J. Langley, A.J. Peacock, O. Sitbon, N. Galié
- PS21** AUTOANTIBODY PROFILE IN SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY HYPERTENSION  
V. Sobanski, S. Nihtyanova, B. Lynch, B. Schreiber, J. Harvey, C. Handler, C. Denton, G. Coghlan
- PS22** RELEVANCE OF THE 6-MINUTE WALKING TEST IN ASSESSING THE SEVERITY OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS, WITHOUT INTERSTITIAL LUNG DISEASE  
S. Sanges, D. Launay, O. Sitbon, E. Hachulla, L. Mouthon, L. Guillevin, L. Rottat, P. Clerson, J.F. Cordier, G. Simonneau, M.Humbert
- PS23** COST SAVINGS WITH A BIOMARKER-BASED SCREENING ALGORITHM FOR PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS  
A. Quinlivan, V. Thakkar, W. Stevens, D. Prior, C. Rabusa, P. Youssef, E. Gabbay, J. Roddy, J. Walker, J. Zochling, J. Sahhar, P. Nash, S. Lester, C.Hill, M. Rischmueller, S. Proudman, M. Nikpour

- PS24** **VALUE OF SYSTOLIC PULMONARY ARTERIAL PRESSURE AS A PROGNOSTIC FACTOR OF DEATH IN SYSTEMIC SCLEROSIS EUSTAR POPULATION**  
E. Hachulla, P. Clerson, P. Airò, G. Cuomo, Y. Allanore, P. Caramaschi, E. Rosata, PE. Carreira, V. Ricciardi, M. Sarraco, CP. Denton, G. Riemekasten, M.R. Pozzi, S. Zeni, C. Mihai, S. Ullman, O. Distler, S. Rednic, V. Smith, UA. Walker
- PS25** **ABERRANT BMP SIGNALLING MAY CONTRIBUTE TO PULMONARY COMPLICATIONS IN A TGF DEPENDENT MURINE MODEL OF SCLERODERMA**  
A. Gilbane, E C. Derrett-Smith, A. Pearce, C P. Denton, A M. Holmes
- PS26** **CHARACTERISATION OF LATE-OUTGROWTH ENDOTHELIAL PROGENITOR CELLS FROM SYSTEMIC SCLEROSIS PATIENTS**  
R. Good, S. Trinder, S. Ahmed Abdi, R. Yu, C.P. Denton, D. Abraham, A. Holmes
- PS27** **AUTOANTIBODIES TARGETING ANGIOTENSIN TYPE 1 AND ENDOTHELIN TYPE A RECEPTORS AS BIOMARKERS AND MEDIATORS OF SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION**  
M. Becker, A. Kill, M. Kutsche, J. Günther, A. Rose, C. Tabeling, M. Witzernath, A. Kühn, H. Heidecke, H. Ghofrani, H. Tiede, N. Nickel, M. Hoeper, I. Lukitsch, M. Gollasch, W. Kuebler, S. Bock, G.-R. Burmester, D. Dragun, G. Riemekasten
- PS28** **SUBCLINICAL BIVENTRICULAR SYSTOLIC FUNCTION IS IMPAIRED IN PATIENTS WITH SYSTEMIC SCLEROSIS: A SPECKLE TRACKING-BASED ECHOCARDIOGRAPHIC STUDY**  
ST. Sahin, S. Yurdakul, N. Yilmaz, Y. Cagatay, S. Aytekin, S. Yavuz
- PS29** **IMPAIRED FUNCTIONAL CAPACITY IN PATIENTS WITH SYSTEMIC SCLEROSIS IS RELATED TO RIGHT VENTRICLE DYSFUNCTION**  
E. Kucharz, K. Mizia-Stec, K. Gieszczyk, A. Sikora-Puz, M. Haberka, M. Mizia, J. Pajak, J. Baron, K. Gruszczynska, M. Widuchowska, M. Kopec-Medrek, A.Kotulska, Z. Gasior
- PS30** **MMP12 CONTRIBUTES TO HEART AND SKIN FIBROSIS IN ANGIOTENSIN II MODEL**  
L. Stawski, M. Trojanowska, P. Haines
- PS31** **RELATIONSHIP BETWEEN INTERLEUKIN-6 AND CARDIAC INVOLVEMENT IN SYSTEMIC SCLEROSIS**  
Z. Jurisic, D. Martinovic-Kaliterna, D. Krstulovic-Marasovic, D. Perkovic, V. Carevic, J. Morovic-Vergles
- PS32** **EXTENSION OF CARDIAC DAMAGE THROUGH THE DELAYED ENHANCEMENT OF CARDIAC MAGNETIC RESONANCE: PREDICTIVE VALUE OF A COMBINED APPROACH BASED ON CLINICAL AND LABORATORY FINDINGS, EKG-HOLTER AND CARDIAC MR**  
S. Bosello, G. De Luca, A. Meduri, G. Berardi, M. Rucco, F. Parisi, G. Canestrari, A. Capacci, M. Correria, L. Bonomo, G. Ferraccioli
- PS33** **KEY ROLE OF CARDIAC BIOMARKERS IN THE ASSESSMENT OF SYSTEMIC SCLEROSIS: CONTRIBUTION OF HIGH SENSITIVITY CARDIAC TROPONIN**  
J. Avouac, C. Meune, C. Chenevier-Gobeaux, D. Borderie, A. Kahan, Y. Allanore
- PS34** **THE ROLE OF INFLAMMATORY PROGENITORS IN MYOCARDIAL FIBROGENESIS IN THE INFLAMMATORY DILATED CARDIOMYOPATHY**  
G. Kania, P. Blyszczuk, B. Müller-Edenborn, S. Behnke, C. Berthonneche, T. Pedrazzini, T.F. Lüscher, U. Eriksson, O. Distler
- PS35** **AN INTERNATIONAL COLLABORATION TO CONDUCT LARGE-SCALE TRIALS OF NON-PHARMACOLOGICAL INTERVENTIONS IN SCLERODERMA: THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN)**  
L. Kwakkenbos, L. Jewett, B. Thombs, SPIN investigators
- PS36** **EARLY MORTALITY IN AUSTRALIAN AND CANADIAN SCLERODERMA PATIENTS: RATIONALE FOR ESTABLISHING A MULTI-NATIONAL INCEPTION COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
M. Nikpour, M. Hudson, W. Stevens, C. Rabusa, S. Tatibouet, S. Proudman, M. Baron
- PS37** **IMPACT OF AUTOANTIBODY PROFILE ON SURVIVAL IN SYSTEMIC SCLEROSIS**  
S. Nihtyanova, V. Ong, C. Denton

- PS38** **DEVELOPING AN INTERVENTION FOR BODY IMAGE DISTRESS IN SYSTEMIC SCLEROSIS: AN UPDATE FROM THE SCLERODERMA PATIENT-CENTERED INTERVENTION NETWORK (SPIN)**  
V. Malcarne, M. Mayes, S. Assassi, R. Fox, S. Gholizadeh, K. Gottesman, D. Harcourt, L. Kwakkenbos, L. Jewett, C. Mendelson, S. Mills, N. Rumsey, T. Strohauser, H. Williamson, B. Thombs
- PS39** **IMPACT OF MALE SEX ON SURVIVAL IN SYSTEMIC SCLEROSIS**  
H. Hussein, C. Chau, S.R. Johnson
- PS40** **APPEARANCE DISSATISFACTION, SOCIAL DISCOMFORT, AND HELPLESSNESS IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
S. Gholizadeh, S. Mills, R. Fox, P. Clements, S. Kafaja, V. Malcarne, D. Khanna, D. Furst
- PS41** **PREDICTION OF WORSENING OF SKIN FIBROSIS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS USING THE EULAR SCLERODERMA TRIALS AND RESEARCH (EUSTAR) REGISTRY AND VALIDATION IN A SECOND COHORT**  
B. Maurer, N. Graf, B.A. Michel, C. Metzsig, V. Lanius, D. Khanna, O. Distler
- PS42** **MRI INFLAMMATORY LESIONS OF THE HAND COULD BE PREDICTORS OF DIGITAL ULCERS, DISEASE ACTIVITY AND LOWER FUNCTIONAL CAPACITY IN SYSTEMIC SCLEROSIS**  
B. Stamenkovic, A. Stankovic, J. Nedovic, S. Stojanovic, V. Zivkovic, A. Dimic, N. Damjanov
- PS43** **EVALUATION OF BLOOD PERFUSION IN DIFFERENT SKIN AREAS OF SYSTEMIC SCLEROSIS PATIENTS BY LASER SPECKLE CONTRAST ANALYSIS AND CORRELATIONS WITH NAILFOLD MICROANGIOPATHY EXTENT**  
A. Sulli, B. Ruaro, F. Ravera, D. Stanciu, C. Pizzorni, M. Cutolo
- PS44** **CORRELATION BETWEEN BLOOD PERFUSION AND DERMAL THICKNESS IN DIFFERENT SKIN AREAS OF SYSTEMIC SCLEROSIS PATIENTS**  
B. Ruaro, A. Sulli, E. Alessandri, G. Ferrari, M.A. Cimmino, M. Cutolo
- PS45** **STABILISATION OF MICROCIRCULATION IN EARLY SYSTEMIC SCLEROSIS PATIENTS WITH DIFFUSE SKIN INVOLVEMENT FOLLOWING RITUXIMAB TREATMENT**  
V. Smith, C. Pizzorni, V. Riccieri, S. Decuman, Y. Piette, A. Sulli, E. Deschepper, F. De Keyser, M. Cutolo
- PS46** **ASSESSMENT OF SKIN BLOOD FLOW AND STRUCTURE IN LOCALISED SCLERODERMA USING NON-INVASIVE IMAGING**  
A. Murray, T. Moore, J. Manning, G. Dinsdale, J. Wilkinson, M. Bhushan, C.E.M. Griffiths, A.L. Herrick
- PS47** **VIRTUAL TOUCH IMAGING AND QUANTIFICATION™: IS IT POSSIBLE TO DISTINGUISH “UNAFFECTED” SKIN IN SCLERODERMA PATIENTS FROM HEALTHY SKIN?**  
T. Santiago, M. Coutinho, M.J. Salvador, F. Delgado, A.C. Redmond, J.A.P. Da Silva
- PS48** **IMAGING OF SCLERODERMA WITH OPTICAL COHERENCE TOMOGRAPHY**  
H.C. Ring, A. Hussain, M. Mogensen
- PS49** **TOWARDS PERSONALIZED MEDICINE: MOLECULAR DIAGNOSTICS FOR SYSTEMIC SCLEROSIS - UTILIZING GENE EXPRESSION PROFILING TO GUIDE PATIENT MANAGEMENT**  
Y. Nesbeth, T. Wood, M. Hinchcliff, S. Podluszky, J. Reder, M. Whitfield
- PS50** **ANTI IL-6 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS**  
R. Baytner-Zamir, Y. Levy
- PS51** **SAFETY AND EFFICACY OF COMBINED B CELL-DEPLETION THERAPY WITH RITUXIMAB AND CYCLOPHOSPHAMIDE IN SYSTEMIC SCLEROSIS**  
L. Picco, G. De Marchi, E. Di Poi, P. Masolini, S. De Vita
- PS52** **5-YEAR FOLLOW UP OF ABATACEPT THERAPY FOR SYSTEMIC SCLEROSIS WITH CHRONIC ARTHRITIS**  
E. Di Poi, P. Masolini, G. De Marchi, L. Picco, S. De Vita
- PS53** **WHAT ARE SYSTEMIC SCLEROSIS-RELATED CALCINOSSES MADE OF AND CAN WE DISSOLVE THEM?**  
C. Lydon, T. Lowe, P. Withers, A. Herrick, P. O'Brien, R. Winpenny

- PS54** **ANTICENTROMERE ANTIBODY, DISEASE DURATION AND HISTORY OF SURGICAL DEBRIDEMENTS PREDICT CALCINOSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
M. Mahmood, J. Wilkinson, J. Manning, A. Herrick
- PS55** **ANTI-CARBAMYLATED PROTEIN ANTIBODIES ARE PRESENT IN SYSTEMIC SCLEROSIS**  
V. Riccieri, I. Bartosiewicz, M. Pendolino, K. Stefanantoni, N. Iannace, C. Alessandri, G. Valesini
- PS56** **THE DEVELOPMENT OF A MODIFIED HAND MOBILITY IN SCLERODERMA TEST AND ITS POTENTIAL AS AN OUTCOME MEASURE IN SYSTEMIC SCLEROSIS**  
G. Sandqvist, J.Å. Nilsson, D.M. Wuttge, R. Hesselstrand
- PS57** **ANALYSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS AND RHEUMATOID ARTHRITIS OVERLAP SYNDROME.**  
A. Parma, A. Della Rossa, A. D'Ascanio, S. Barsotti, C. Stagnaro, S. Bombardieri
- PS58** **ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR IN SYSTEMIC SCLEROSIS – PREVALENCE AND USEFULNESS.**  
E. Wielosz, M. Dryglewska, M. Majdan
- PS59** **EFFECTS OF PRESSURE RELIEVING INSOLES FOR FOOT PROBLEMS IN PEOPLE WITH SSC: THE PISCES RANDOMIZED CONTROLLED TRIAL**  
A. Redmond, B. Alcaccer-Pitarch, J. Gray, C. Denton, A. Herrick, N. Navarro-Coy, H. Collier, L. Loughrey, S. Pavitt, H. Siddle, J. Wright, P. Helliwell, P. Emery, M. Buch
- PS60** **HAND DISABILITY IN PATIENTS WITH SYSTEMIC SCLEROSIS: THE ROLE OF AN INDIVIDUALIZED REHABILITATION PROGRAM**  
A. Volpe, G. Apolloni, G. Barausse, R. Bortolotti, F. Cavatorta, S. Peccatori, M. Felicetti, C. Ferri, G. Paolazzi
- PS61** **SYSTEMIC SCLEROSIS-RELATED SYNOVITIS: IMAGING FEATURES AND HISTOLOGICAL EXAMINATION OF THE SYNOVIAL TISSUE**  
M. Stoenoiu, C. Galant, M. Vanthuyne, O. Barbier, O. Cornu, BR. Lauwerys, A. Nzeusseu-Toukap, F.E. Lecouvet, F. A. Houssiau
- PS62** **EVALUATION OF THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM (PROMIS®) GASTROINTESTINAL (GI) SYMPTOMS MEASURES IN SYSTEMIC SCLEROSIS (SSC)**  
D. Khanna, L. Chang, G. Melmed, R. Hays, P. Khanna, B. Spiegel
- PS63** **UPPER GASTROINTESTINAL BLEEDING PREDICTS HIGHER MORTALITY IN SYSTEMIC SCLEROSIS PATIENTS**  
Y. Braun-Moscovici, D. Markovits, I. Gralnek, K. Toledano, R. Beshara-Garzo, A. Dagan, A. Rozin, Y. Chowers, A. Balbir-Gurman
- PS64** **NUTRITIONAL SUPPORT IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
V. Ortiz-Santamaria, A. Recasens, C. Puig, C. Soldevila, J. Cuquet
- PS65** **VASCULAR EVENTS ARE RISK FACTORS FOR ANAL INCONTINENCE IN SYSTEMIC SCLEROSIS: A STUDY ON MORPHOLOGY AND FUNCTIONAL PROPERTIES AS MEASURED BY ANAL ENDOSONOGRAPHY AND MANOMETRY**  
R. Hesselstrand, K. Andréasson, M. Starck, A. Scheja, I. Bartosik
- PS66** **FAECAL LEVELS OF CALPROTECTIN IN SYSTEMIC SCLEROSIS ARE STABLE OVER TIME AND ARE HIGHER COMPARED TO PRIMARY SJÖGREN'S SYNDROME AND RHEUMATOID ARTHRITIS**  
K. Andréasson, T. Saxne, A. Scheja, I. Bartosik, T. Mandl, R. Hesselstrand
- PS67** **GASTROINTESTINAL MUCOSAL ABNORMALITIES USING VIDEOCAPSULE ENDOSCOPY IN SYSTEMIC SCLEROSIS**  
I. Marie, M. Antonietti, E. Hachulla, B. Bienvenu, A. Smail, P. Duhaut, S. Dominique, PY. Hatron, E. Houivet, H. Levesque, J. Benichou, P. Ducrotte
- PS68** **ASSESSMENT OF VALIDITY OF GASTROINTESTINAL MORPHOLOGY PROCEDURES AND BACTERIAL OVERGROWTH TESTS USED IN SYSTEMIC SCLEROSIS, BASED ON OMERACT CRITERIA**  
Y. Braun-Moscovici, M. Braun, D. Khanna, A. Balbir-Gurman, D.E. Furst

- PS69** **SEXUAL DYSFUNCTION: THE PHYSICAL AND PSYCHOLOGICAL BURDEN ON WOMEN IN SYSTEMIC SCLEROSIS**  
T. Ngcozana, C. Denton, V. Ong
- PS70** **IN WOMEN WITH SYSTEMIC SCLEROSIS, SEXUAL FUNCTION IS AFFECTED BY DISEASE-RELATED AND PSYCHOLOGICAL CONCERNS**  
A. Del Rosso, S. Maddali Bongi, S. Mikhaylova, M. Baccini, M. Matucci Cerinic
- PS71** **SEXUAL DYSFUNCTION IS ASSOCIATED WITH ANXIETY AND HIGHER BODY MASS INDEX IN WOMEN WITH SYSTEMIC SCLEROSIS**  
M. Coutinho, I. Ruela, T. Santiago, C. Duarte, J.A.P. da Silva, M.J. Salvador
- PS72** **THE VASCULAR HYPOTHESIS OF FEMALE AND MALE SEXUAL DYSFUNCTION**  
E. Rosato, S. Quarta, L. Trombetta, S. Pisarri, F. Salsano
- PS73** **IMPRESS 2 (INTERNATIONAL MULTICENTRIC PROSPECTIVE STUDY ON PREGNANCY IN SYSTEMIC SCLEROSIS). PROSPECTIVE, CASE-CONTROL STUDY OF PREGNANCY IN SYSTEMIC SCLEROSIS**  
C. Di Blasi Lo Cuccio, V. Ramoni, M. Taraborelli, M. Ostensen, A. Mazzone, V. Steen, G. Valentini, M. Limonta, A. Brucato, A. Tincani, M. Matucci-Cerinic
- PS74** **ALLOGENIC SKIN GRAFTING FOR SYSTEMIC SCLEROSIS ULCERS: PRELIMINARY DATA OF AN ITALIAN COHORT**  
S. Barsotti, V. Mattaliano, A. d'Ascanio, G. Mosti, A. Della Rossa, C. Ferri, E. Giraldi, D. Giuggioli, C. Mattaliano, S. Bombardieri
- PS75** **AUTOLOGOUS FAT TRANSFER FOR DIGITAL ULCERS TREATMENT IN SYSTEMIC SCLEROSIS**  
G. Erba, E. Allevi, I. Mazzola, M. Del Bene, M.R. Pozzi
- PS76** **LUNG TRANSPLANTATION IN SISTEMIC SCLEROSIS: EXPERIENCE IN A SPANISH CENTER**  
A. Fernández-Codina, C. Simeón, C. Berastegui, G. Silveira, A. Guillen, V. Fonollosa, V. Monforte, M. Vilardell-Tarriés, A. Román
- PS77** **LONG TERM EFFICACY OF PERIORAL AUTOLOGOUS FAT TRANSPLANTATION ON SCLERODERMA SKIN FIBROSIS: A CONTROLLED STUDY VERSUS HYALURONIC ACID FILLER**  
N. Del Papa, D. Sambataro, E. Zaccara, W. Maglione, G. Di Luca, A. Parafioriti, E. Armiraglio, A. Di Bernardo, F. Cavigglioli, V. Vinci, M. Klingner
- PS78** **NEW FAT-DERIVED PRODUCTS FOR TREATING INDUCED-SKIN LESIONS OF SCLERODERMA IN NUDE MICE**  
A. Daumas, N. Serratrice, D. Ould Ali, P. Nguyen, L. Giraudeau, J. Veran, J. Magalon, L. Andrac-Meyer, B. Granel, G. Magalon
- PS79** **THE USE OF ADIPOSE-DERIVED REGENERATIVE CELLS (ADRCs) IN THE TREATMENT OF SCLERODERMA OF THE HANDS: A PROSPECTIVE TRIAL**  
G. Magalon, A. Daumas, P. Nguyen, F. Sabatier, J. Veran, L. Graudo, J. Eraud, E. Jouve, B. Granel
- PS80** **NO CORRELATION OF CD4+ LYMPHOPENIA AND CLINICAL RESPONSE TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS**  
M. Wagner, I. Kötter, W. Vogel, L. Kanz, J. Henes
- PS81** **INTEREST OF MICRO REINJECTION OF AUTOLOGOUS ADIPOSE TISSUE IN THE FACE OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
N. Sautereau, J. Eraud, A. Daumas, L. Giraudo, F. Sabatier, G. Magalon, B. Granel
- PS82** **HUMAN ADIPOSE-DERIVED STROMAL CELLS FOR CELL-BASED THERAPIES IN THE TREATMENT OF COUTANEOUS MANIFESTATIONS IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS (SSC)**  
N. Scuderi, P. Fino, M.G. Onesti
- PS83** **ANGIOTENSIN RECEPTOR TYPE 1 AND ENDOTHELIN RECEPTOR TYPE A ON IMMUNE CELLS MEDIATE MIGRATION AND THE EXPRESSION OF IL-8 AND CCL18 WHEN STIMULATED BY AUTOANTIBODIES FROM SYSTEMIC SCLEROSIS PATIENTS**  
J. Günther, A. Kill, MO. Becker, E. Siegert, M. Radic, G. Riemekasten

- PS84 ANTI-AT1R AND ANTI-ETAR AUTOANTIBODIES FROM PATIENTS WITH SSC AND THEIR AGONISTIC EFFECTS**  
 A. Kill, C. Tabeling, A. Kühl, J. Günther, M. O. Becker, H. Heidecke, D. Dragun, G.R. Burmester, G. Riemekasten
- PS85 SYSTEMIC SCLEROSIS SERA AFFECT ANGIOGENESIS, WOUND HEALING CAPACITY AND MIGRATION OF DERMAL BLOOD MICROVASCULAR ENDOTHELIAL CELLS: THERAPEUTIC IMPLICATIONS OF CYCLOPHOSPHAMIDE**  
 A. Borghini, M. Manetti, F. Nacci, E. Romano, A.F. Milia, S. Guiducci, M. Matucci-Cerinic, L. Ibba-Manneschi, E. Weber
- PS86 FROM MICROVASCULATURE TO FIBROBLAST: CONTRIBUTION OF ANTI-ENDOTHELIAL CELL ANTIBODIES (AECA) IN SYSTEMIC SCLEROSIS**  
 C. Corallo, B. Franci, A. Montella, F. D'Onofrio, R. Nuti, N. Giordano
- PS87 CIRCULATING ANGIOGENIC FACTORS IN SSC PATIENTS – ASSOCIATION WITH CLINICAL MANIFESTATIONS**  
 M. Madej, A. Luczak, B. Nowak, E. Morgiel, L. Korman, P. Wiland
- PS88 CIRCULATING ENDOTHELIAL MICROPARTICLES REFLECT MICROVASCULAR IMPAIRMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
 O. Kowal-Bielecka, M. Bielecki, M. Michalska-Jakubus, D. Krasowska
- PS89 IGG SUBCLASSES OF AUTOANTIBODIES DIRECTED AGAINST THE ANGIOTENSIN RECEPTOR TYPE 1 AND THE ENDOTHELIN RECEPTOR TYPE A AND THEIR CLINICAL RELEVANCE**  
 J. Günther, A. Kill, M.O. Becker, E. Siegert, H. Heidecke, G. Riemekasten
- PS90 DECREASED EXPRESSION OF NEUROFILIN-1 IN SYSTEMIC SCLEROSIS: POTENTIAL CONTRIBUTION TO IMPAIRED ANGIOGENESIS**  
 E. Romano, M. Manetti, C. Mazzotta, I. J. Da Silva Chora, S. Bellando-Randone, J. Blagojevic, L. Ibba-Manneschi, M. Matucci-Cerinic, S. Guiducci
- PS91 INVOLVEMENT OF PLEXIND1/SEMAPHORIN 3E PATHWAY ON THE DYSREGULATION OF VASCULAR TONE CONTROL IN SSC PATIENTS**  
 C. Mazzotta, E. Romano, C. Bruni, M. Manetti, G. Lepri, S. Bellando-Randone, J. Blagojevic, I. J. Da Silva Chora, A. Radicati, M. Matucci-Cerinic, S. Guiducci
- PS92 DECREASED EXPRESSION OF THE ENDOTHELIAL CELL-DERIVED FACTOR EGFL7 CONTRIBUTES TO IMPAIRED ANGIOGENESIS AND VASCULOGENESIS IN SYSTEMIC SCLEROSIS**  
 M. Manetti, S. Guiducci, E. Romano, J. Avouac, I. Rosa, B. Ruiz, G. Lepri, S. Bellando-Randone, L. Ibba-Manneschi, Y. Allanore, M. Matucci-Cerinic
- PS93 NAILFOLD CAPILLAROSCOPIC ASSESSMENT AND VASCULAR BIOMARKERS IN SYSTEMIC SCLEROSIS: LOW CD40L LEVELS IN PATIENTS WITH LATE SCLERODERMA PATTERNS**  
 Y. Yalcinkaya, S. Cinar, S. Kamali, O. Pehlivan, N. Alpay, L. Ocal, G. Deniz, M. Inanc
- PS94 DIAGNOSTIC TARGETS REVEALED BY HIGH-RESOLUTION PROTEIN PROFILING OF HUMAN PLASMA MICROPARTICLES**  
 L. Iversen, O. Østergaard, S. Jacobsen, N. Heegaard
- PS95 S100A4 SERUM LEVELS CORRELATE WITH SKIN FIBROSIS, LUNG INVOLVEMENT AND DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS**  
 M. Tomcik, L. Andres Cerezo, S. Skacelova, M. Komarc, R. Becvar, M. Grigorian, J.H.W. Distler, L. Senolt
- PS96 SECRETED FRIZZLED-RELATED PROTEIN 4 CAN BE INDUCED BY TRANSFORMING GROWTH FACTOR-BETA, IS REGULATED BY CAVEOLIN-1 AND CAN INDUCE NON-CANONICAL WNT SIGNALING IN FIBROBLASTS**  
 J. Gillespie, A. Giuseppina, P. Emery, M.F. McDermott, F. Del Galdo
- PS97 TARGETING IL-6 BY BOTH PASSIVE OR ACTIVE IMMUNIZATION STRATEGIES PREVENTS INFLAMMATION-DRIVEN SKIN FIBROSIS**  
 J. Avouac, L. Desallais, M. Fréchet, M. Elhai, J.F. Zagury, Y. Allanore

- PS98** **ENDOTHELIN-1 MEDIATES DOWNSTREAM PROFIBROTIC EFFECTS BY TRANSFORMING GROWTH FACTOR-BETA 1 IN SYSTEMIC SCLEROSIS SKIN FIBROBLASTS**  
T. Higuchi, Y. Kawaguchi, K. Takagi, Y. Ota, Y. Katsumata, T. Gono, H. Yamanaka
- PS99** **THE ROLE OF MCSF AND ENDOTHELIN 1 IN FIBROCYTE DIFFERENTIATION**  
S. Trinder, X. Shi-wen, B. Ahmed-Abdi, R. Good, A. Gilbane, C. Denton, D. Budd, D. Abraham, A. Holmes
- PS100** **SIMVASTATIN MODULATES AORTIC INTIMA/MEDIA THICKNESS IN AN ANIMAL MODEL OF SYSTEMIC SCLEROSIS**  
G. Bagnato, A. Bitto, G. Pizzino, W.N. Roberts, D. Altavilla, F. Squadrito, G. Bagnato, A. Saitta
- PS101** **SUSCEPTIBILITY OR RESISTANCE TO EXPERIMENTAL LUNG FIBROSIS IS PREDICTED BY RESIDENT LUNG FIBROBLAST GENE EXPRESSION SIGNATURE**  
E. Derrett-Smith, R. Hoyles, K. Khan, D. Abraham, C. Denton
- PS102** **EXCESSIVE FIBROSIS AND PULMONARY VASCULAR REMODELING IN FRA-1 TRANSGENIC MICE**  
H. Yasuoka, Y. Okazaki, A. Tam, Y. Tamura, I. Takada, K. Matsuo, T. Takeuchi, M. Kuwana
- PS103** **INCREASED FREQUENCY OF INTERLEUKIN-2 PRODUCTION BY TH17 LYMPHOCYTES IN PERIPHERAL BLOOD OF SYSTEMIC SCLEROSIS PATIENTS**  
M.G. Santiago, M. Raposo, C. Duarte, M.J. Salvador, A. Paiva, J.A.P. Da Silva
- PS104** **ROLE OF IL-13-PRODUCING CD8+ T CELLS IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS**  
P. Fuschiotti, A. T. Larregina, C. Feghali-Bostwick, J. Devlin, D.B. Stolz, T. A. Medsger Jr.
- PS105** **TOLL LIKE RECEPTOR 3: A CROSSROAD IN SCLERODERMA ETIOPATHOGENESIS**  
C.B. Chighizola, E. Raschi, L. Cesana, S.C. Uceda Renteria, M. Biggioggero, M.O. Borghi, P.L. Meroni
- PS106** **ENHANCED IL-8 PRODUCTION BY MONOCYTES IN SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY FIBROSIS**  
M.G. Santiago, S. Horta, M.J. Salvador, A. Paiva, J.A.P. Da Silva
- PS107** **MOLECULAR ASPECTS OF IL-13 UP-REGULATION BY CD8+ T CELLS FROM SSC PATIENTS**  
S. Cascio, A. Moss, M. Jessup, D. B. Stolz, C. Milcarek, T. A. Medsger, P. Fuschiotti
- PS108** **EXPRESSION OF THE TRANSCRIPTION FACTOR FORKHEAD BOX E3 (FOXE3) IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
E. Favoino, I. E. Favia, L. Digiglio, F. Perosa
- PS109** **ANTIBODIES ANTI-RO/SSA IN SYSTEMIC SCLEROSIS**  
I. Cavazzana, M. Fredi, M. Taraborelli, P. Airo', A. Tincani, F. Franceschini
- PS110** **MEMORY (CD27+) B CELL IMPAIRMENT IS A CHARACTERISTIC FEATURE OF PATIENTS WITH SYSTEMIC SCLEROSIS AND PULMONARY FIBROSIS**  
L. Sakkas, A. Mavropoulos, T. Simopoulou, A. Varna, C. Liaskos, C. Katsiari, DP. Bogdanos
- PS111** **IRF8 GENE CONTRIBUTES TO DISEASE SUSCEPTIBILITY AND INTERACTS WITH NF-KB BY MODULATING INTERFERON SIGNATURE IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
Ml. Arismendi, M. Giraud, N. Ruzehaji, P. Dieudé, B. Ruiz, P. Airo, M. Matucci-Cerinic, G. Cuomo, E. Hachulla, P. Caramaschi, V. Riccieri, J. Avouac, C. Kayser, Y. Allanore
- PS112** **ACTIVATION OF LIVER X RECEPTORS INHIBITS EXPERIMENTAL FIBROSIS BY INTERFERING WITH INTERLEUKIN-6 RELEASE FROM MACROPHAGES**  
C. BEYER, J. Beer, K. Palumbo-Zer, P. Zerr, A. Distler, C. Dees, L. Munoz, G. Kroenke, S. Uderhardt, O. Distler, T. Ovarecz, G. Schett, J. Distler
- PS113** **CORRELATION BETWEEN SHORTER DISEASE DURATION IN SYSTEMIC SCLEROSIS (SSC) AND ANTI-COLLAGEN TYPE V**  
M. Ugolini, E. Mantovani, V. Dinis, V. Bonoldi, A. Ribeiro, N. Yoshinari, D. Andrade



- PS114** **SYSTEMIC SCLEROSIS AND OCCUPATIONAL EXPOSURE: A CASE CONTROL STUDY OF 100 PATIENTS AND 300 CONTROLS**  
I. Marie, JF. Gehanno, M. Bubenheim, A.B. Duval-Modeste, P. Joly, S. Dominique, P. Bravard, D. Noel, J. Weber, J. Benichou, H. Levesque
- PS115** **A GENOME-WIDE ASSOCIATION STUDY FOLLOW-UP SUGGESTS A POSSIBLE ROLE FOR PPARG IN SYSTEMIC SCLEROSIS SUSCEPTIBILITY**  
E. Lopez Isac, C.P. Simeon, J.A. Roman-Ivorra, SSG. Spanish Scleroderma Group, L. Beretta, C. Lunardi, N. Hunzelmann, G. Riemekasten, T. Witte, JHW. Distler, AJ. Schuerwegh, MC. Vonk, AE. Voskuyl, C. Fonseca, C. Denton, A. Herrick, S. Assassi, MD. Mayes, TRDJ. Radstake, J. Martin
- PS116** **PREVALENCE OF ANTI-RNA POLYMERASE III ANTIBODIES IN SYSTEMIC SCLEROSIS: NEW DATA FROM A FRENCH COHORT, SYSTEMATIC REVIEW AND META-ANALYSIS**  
V. Sobanski, L. Dauchet, G. Lefevre, M. Lambert, S. Morell-Dubois, T. Sy, E. Hachulla, P.Y. Hatron, D. Launay, S. Dubucquoi
- PS117** **SEMAPHORIN 3A AS A POSSIBLE IMMUNOREGULATOR IN SYSTEMIC SCLEROSIS**  
D. Rimar, I. Rosner, G. Slobodin, M. Rozenbaum, K. Halasz, T. Haj, N. Jiries, L. Kaly, N. Boulman, R. Daood, Z. Vadasz
- PS118** **INFLUENCE OF ALPHA 2 DO COLLAGEN V OVEREXPRESSION IN PHYSIOPATHOLOGY OF FIBROSIS SYSTEMIC SCLEROSIS PATIENTS**  
J. Morais, P. Martin, APP. Velosa, PC. Andrade, IB. Cruz, EC. Miracca, FAC. Barrence FAC, S. Carrasco, C. Goldeinstein-Schainberg, MA. Nagai, ER. Parra, VL. Capelozzi, WR. Teodoro
- PS119** **SERUM FREE LIGHT CHAINS OF IMMUNOGLOBULINS ARE ASSOCIATED WITH DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS : A PROSPECTIVE AND CONTROLLED STUDY**  
A. Lantieri, S. Dubucquoi, E. Hachulla, C. Langlois, M. Lambert, S. Vuye, C. Hauspie, P.Y. Hatron, D. Launay
- PS120** **COLLAGEN CROSS LINKING ENZYMES LOXL2 AND PLOD2 SHOW NO ASSOCIATION WITH SYSTEMIC SCLEROSIS**  
S. Guerra, S. Ziaj, B. Ahmed Abdi, K. Khan, I. Papaioannou, C. Denton, D. Abraham, C. Fonseca
- PS121** **VITAMIN D ANTIBODIES IN SYSTEMIC SCLEROSIS PATIENTS: ANTIBODIES PRESENCE AND CLINICAL AND LABORATORY CORRELATIONS**  
N.N. Carmel, A. Lavrov, P. Rotman, Y. Levy
- PS122** **A LOSS OF TELOCYTES CHARACTERIZES FIBROSIS OF MULTIPLE ORGANS IN SYSTEMIC SCLEROSIS**  
M. Manetti, I. Rosa, L. Messerini, M. Matucci-Cerinic, L. Ibba-Manneschi
- PS123** **INCREASED FREQUENCY OF TH1 AND TC1 LYMPHOCYTES PRODUCING TUMOR NECROSIS FACTOR ALPHA IN PERIPHERAL BLOOD OF LATE-STAGE SYSTEMIC SCLEROSIS**  
M.G. Santiago, M. Raposo, C. Duarte, M.J. Salvador, A. Paiva, J.A.P. Da Silva
- PS124** **HELICOBACTER PYLORI AS A TRIGGER OF SYSTEMIC SCLEROSIS: IMMUNOLOGICAL ASPECTS**  
C. Liaskos, A. Varna, T. Simopoulou, A. Mavropoulos, M. Mytilinaiou, El. Rigopoulou, DP. Bogdanos, LI. Sakkas
- PS125** **ROLE OF ANGIOSTATIN AND ENDOSTATIN IS SYSTEMIC SCLEROSIS**  
I. Almeida, A. Gomes, A. Puga, I. Silva, M. Lima, C. Vasconcelos
- PS126** **ROLE OF CD8+ LYMPHOCYTES IN SYSTEMIC SCLEROSIS**  
I. Almeida, S. Vieira Silva, M. Santos, M. Lima, C. Vasconcelos
- PS127** **PROPYLTHIOURACIL ATTENUATES AORTIC VASCULOPATHY IN AN ANIMAL MODEL OF SYSTEMIC SCLEROSIS**  
G. Bagnato, A. Bitto, G. Pizzino, W.N. Roberts, D. Altavilla, F. Squadrito, G. Bagnato, A. Saitta
- PS128** **THE RELATIONSHIP BETWEEN NAILFOLD CAPILLAROSCOPIC ASSESSMENT AND TELANGIECTASIA SCORE WITH SEVERITY OF PERIPHERAL VASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS**  
Y. Yalcinkaya, O. Pehlivan, N. Alpay, A. Omma, B. Erer, S. Kamali, L. Ocal, M. Inanc

- PS129** EFFICACY OF BOSENTAN IN THE TREATMENT OF RAYNAUD'S PHENOMENON: ANALYSIS OF THREE COHORTS OF PATIENTS  
S. Parisi, M. Scarati, M. Priora, M. Galeazzi, F. Bellisai, S. Manganelli, L. Emmi, E. Beccastrini, A. Ianniello, E. Fusaro
- PS130** CORRELATIONS BETWEEN PERIPHERAL MICROVASCULAR DISEASE SEVERITY AND VITAMIN D SERUM LEVELS IN SYSTEMIC SCLEROSIS PATIENTS  
A. Sulli, S. Paolino, V. Smith, G. Botticella, C. Pizzorni, A. Casabella, B. Seriola, M. Cutolo
- PS131** SCLERODERMA DIGITAL ULCER HEALING: BENEFICIAL ROLE OF BOSENTAN AND OPPONENT ROLE OF SKIN DIGITAL FIBROSIS  
M. Inglese, F. Molinaro, M. Bernal, M. Sperandeo, G. Mazzoccoli, V. D'Alessandro, S. Stisi, A. De Cata
- PS132** DEVELOPMENT OF A MOUSE MODEL OF SCLERODERMA-RELATED SKIN ULCER  
S. Kotzki, J.L. Cracowski, O. Combes, C. Arnaud, D. Godin-Ribuot, M. Roustit
- PS133** CORRELATIONS BETWEEN VIRTUAL TOUCH IMAGING AND QUANTIFICATION ABSOLUTE SKIN STIFFNESS, NAILFOLD CAPILLAROSCOPY PATTERN AND DIGITAL ULCERS IN SYSTEMIC SCLEROSIS PATIENTS  
T. Santiago, M.C. Coutinho, M.J. Salvador, F. Delgado, A.C. Redmond, J.A.P. Da Silva
- PS134** GINKGO BILOBA REDUCES THE DURATION AND SEVERITY OF RAYNAUD'S ATTACKS OF PATIENTS WITH SYSTEMIC SCLEROSIS  
Z. Mirfeizi, M.H. Jocar, M. Mirfeizi
- PS135** BLOOD FLOW IN THE HANDS OF A PREDEFINED HOMOGENEOUS SYSTEMIC SCLEROSIS POPULATION: THE PRESENCE OF DIGITAL ULCERS AND THE IMPROVEMENT WITH BOSENTAN  
J. Meijs, A. Voskuyl, J. Bloemsaat-Minekus, M. Vonk
- PS136** ACUPRESSURE FOR THE TREATMENT OF RAYNAUD'S PHENOMENON: A PILOT RANDOMIZED CONTROLLED TRIAL  
H. Gladue, V. Berrocal, R. Harris, P. Tsou, D. Khanna
- PS137** COMPARISON OF POSTOCCLUSIVE HYPEREMIA IN SYSTEMIC SCLEROSIS AND PRIMARY RAYNAUD'S PHENOMENON  
F. Gaillard-Bigot, M. Roustit, S. Blaise, M. Gabin, C. Cracowski, C. Seinturier, B. Imbert, P. Carpentier, J.L. Cracowski
- PS138** NAILFOLD VIDEOCAPILLAROSCOPY AND SERUM VEGF AS BIOMARKERS OF SEVERITY IN SYSTEMIC SCLEROSIS?  
M. De Santis, F. Cavaciocchi, C. Crotti, A. Ceribelli, A. Laria, B. Marasini, M.S. Massarotti, C. Selmi
- PS139** SCLERODERMA AND DIGITALS ULCERS TREATMENT ACCESS  
C. Bento, N. Cavilla, S. Di Stefano
- PS140** DIGITAL ULCERS IN SYSTEMIC SCLEROSIS  
A. Abdessemed, N. Ait Belabas, S. Benchikh, F. Bougrina, N. Khaldoun, S. Haid, R. Chetouane, R. Djidjik, N. Brahimi, M. Ghaffor, A. Ladjouze
- PS141** EPIDEMIOLOGICAL STUDY FOR THE EARLY DETECTION OF SYSTEMIC SCLEROSIS IN PATIENTS WITH RAYNAUD PHENOMENON  
E. Beltrán-Catalán, JA. Román-Ivorra, C. Feced, J. Alegre
- PS142** EVOLUTION OF PATIENTS WITH SCLERODERMA AND SEVERE DISTAL ISCHEMIC EVENTS AFTER STOPPING TREATMENT WITH BOSENTAN  
F. Garcia-Hernandez, R. Gonzalez-Leon, E. Montero-Mateos, A. Leon-Guisado, I. Porras-Antras, C. Sotomayor-Piedra, M.J. Castillo-Palma
- PS143** BOSENTAN TREATMENT OF DIGITAL ULCERS RELATED TO SYSTEMIC SCLEROSIS  
S. Giancotti, R. Cimino, C. Pintaudi, S. Mazzuca
- PS144** FUNCTIONAL VASCULAR ABNORMALITIES IN SYSTEMIC SCLEROSIS (SSC) MIGHT BE USEFUL FOR DISEASE SUB SETTING: A LASER SPECKLE CONTRAST STUDY  
A. Della Rossa, A. d'Ascanio, C. Stagnaro, S. Barsotti, M. Cazzato, M. Mosca, S. Bombardieri
- PS145** NAILFOLD CAPILLAROSCOPY BY DIGITAL USB-MICROSCOPE: AN INEXPENSIVE AND EASY METHOD FOR IDENTIFYING SCLERODERMA PATTERN  
H. Bitter, G. Myklebust

- PS146** **MICROCIRCULATORY EFFECTS OF ILOPROST ON NEW DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
C. Pintaudi, R. Cimino, S. Giancotti, S. Mazzuca
- PS147** **SURGICAL TREATMENT OF SCLERODERMA – RE-THINKING THE ROLE AND TIMING OF PERIPHERAL SYMPATHECTOMY IN THE HAND**  
J. Chang, A. Momeni, S. Sorice, L. Chung
- PS148** **INTRAVENOUS ILOPROST TREATMENT SIDE EFFECT PROFILE IN PATIENTS WITH DIGITAL ULCERS DUE TO SYSTEMIC SCLEROSIS**  
S. Ugurlu, D. Cevirgen, B. Yalcin
- PS149** **DEVELOPMENT OF A NEW SCORING SYSTEM TO ASSESS DIGITAL ULCERS IN PATIENTS SUFFERING FROM SYSTEMIC SCLEROSIS**  
D. Tomsitz, G. Riemekasten, M. Becker, E. Siegert, H.H. Lee, M. Worm
- PS150** **QUANTITATIVE ANALYSIS OF NAILFOLD CAPILLARY MORPHOLOGY AND CORRELATION WITH RAYNAUD’S PHENOMENON IN PATIENTS WITH FIBROMYALGIA**  
H. Kim, SK. Kim
- PS151** **OBSERVATION PATIENTS WITH RAYNAUD SYNDROM IN SLOVAK POPULATION INCLUDE CAPILLAROSCOPY FINDINGS, USING CAPILLAROSCOPY FOR SEARCHING PATIENT WITH EARLY STAGE OF SCLERODERMA**  
J. Lukac, O. Lukacova, J. Rovensky
- PS152** **COMPUTERIZED NAIL-FOLD VIDEO CAPILLAROSCOPY AND SYSTEMIC SCLEROSIS**  
D. Hakem, N. Ouadahi, A. Berrah
- PS153** **TREATMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: REVIEW OF ELEVEN PATIENTS FROM A SINGLE CENTER AND DISCUSSION ON OUTCOME**  
J. Matos-Costa, R. Almeida, A. A.-Oliveira, P. Pego, Y. Abuowda, I. A.-Câmara, C. Santos, Nedai
- PS154** **EFFECT OF SARPOGRELATE FOR RAYNAUD’S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS**  
T. Makino, M. Jinnin, I. Kajihara, K. Makino, H. Ihn
- PS155** **CURRENT APPROACH TO DIGITAL ULCERS IN SYSTEMIC SCLEROSIS**  
S. Lambova, A. Batalov, H. Dobrev, L. Sapundzhiev, U. Müller-Ladner
- PS156** **BOSENTAN FOR DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS: SINGLE-CENTER EXPERIENCE**  
O. Kucuksahin, A. Ates, U. Ilgrn, B. Ozturk, G. Kinikli, M. Turgay, N. Duzgun
- PS157** **MINIMAL CLINICALLY IMPORTANT INVESTIGATIONS IN SYSTEMIC SCLEROSIS**  
J. Meijs, J. De Vries, N. Ajmone, M. Ninaber, T. Huizinga, A. Schouffoer
- PS158** **COMBINED PULMONARY FIBROSIS AND EMPHYSEMA (CPFE) IN SYSTEMIC SCLEROSIS**  
N. Champiaux, V. Cottin, E. Hachulla, D. Valeyre, H. Nunes, D. Launay, B. Crestani, L. Guillevin, JF. Cordier, L. Mouthon
- PS159** **DYNAMICS OF DISEASE SEVERITY INDEX AND ESCSG ACTIVITY INDEX IN SSC-ASSOCIATED ILD DURING LONG-TERM FOLLOW UP**  
O. Ovsyannikova, O. Koneva, V. Lesnyak, L. Ananieva
- PS160** **THE PREVALENCE AND CLINICAL RELEVANCE OF INTERSTITIAL LUNG DISEASE ON THE HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) IN EARLY SYSTEMIC SCLEROSIS PATIENTS**  
S. Wangkaew, J. Euathrongchit, N. Kasitanon, S. Puntana, W. Louthrenoo
- PS161** **PROGNOSTIC FACTORS OF FUNCTIONAL OUTCOME IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE**  
N. Le Gouellec, J. Salleron, JB. Favier, G. Lefevre, V. Sobanski, T. Perez, PY. Hatron, E. Hachulla, M. Remy-Jardin, D. Launay
- PS162** **INTERSTITIAL LUNG DISEASE IN SOUTH AFRICANS WITH SYSTEMIC SCLEROSIS**  
P. Ashmore, M. Tikly, M. Wong, C. Ickinger
- PS163** **COMPARISON OF INTERSTITIAL LUNG DISEASE CT INDEXES AND PULMONARY FUNCTION VALUES IN SYSTEMIC SCLEROSIS PATIENTS**  
A. Ariani, M. Saracco, E. Bravi, F. Lumetti, E. Arrigoni, R. Pellerito, G. Delsante, F. C. Bodini, N. Sverzellati

- PS164** SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE EVALUATION: COMPARISON BETWEEN SEMIQUANTITATIVE AND QUANTITATIVE CT ASSESSMENTS  
A. Ariani, F. Lumetti, D. Santilli, F. Mozzani, M. Silva, G. Delsante, N. Sverzellati
- PS165** ENHANCED ACTIVATION OF TGF $\beta$ -RELATED SIGNALING MOLECULES IN MONOCYTES FROM HEALTHY AFRICAN AMERICANS AND SSC ILD PATIENTS  
E. Tourkina, C. Reese, B. Perry, J. Heywood, M. Bonner, R.P. Visconti, R.M. Silver, S. Hoffman
- PS166** CLINICAL CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH INTERSTITIAL LUNG DISEASE WHO DO NOT REQUIRE IMMUNOSUPPRESSIVE TREATMENT  
E. Lee, H. Kwon, E. Kang, E. Lee, Y. Song
- PS167** ELEVATED SERUM LEVELS OF TUMOR-ASSOCIATED ANTIGENS IN SYSTEMIC SCLEROSIS: CORRELATION WITH LUNG FIBROSIS  
A. Vacca, V. Ibba, M. Cristo, G. Dessole, P. Garau, V. Mura, M. Piga, G. Porru, F. Figus, M. Dessi', A. Cauli, A. Mathieu
- PS168** RESIDUAL VOLUME: A CANDIDATE AS EARLY MARKER OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS PATIENTS?  
C. Rotondo, E. Praino, E. Lanciano, M. Fornaro, G. Lopalco, M. G. Nivuori, F. Iannone, G. Lapadula
- PS169** A NEW METHOD TO EVALUATE THE EXTENT OF PULMONARY FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS.  
E. Roubi, S. Nyren, L. Bjornadal, E. Svenungsson, A. Nordin
- PS170** POSSIBLE ASSOCIATION OF AMBRISENTAN WITH DETERIORATION OF CONNECTIVE TISSUE DISEASES-ASSOCIATED INTERSTITIAL LUNG DISEASE  
Y. Yamasaki, H. Yamada, K. Tsuchida, H. Ogawa, S. Ozaki
- PS171** LL-37: IS IT A NEW MARKER FOR INTERSTITIAL LUNG DISEASE (ILD) IN SYSTEMIC SCLEROSIS (SSC)?  
M. Hizal, C. Bruni, E. Romano, C. Mazzotta, S. Guiducci, A. Tufan, M. Matucci-Cerinic
- PS172** COMPARISON OF BAL AND SERUM CYTOKINES AND PREDICTIVE VALUE OF SERUM CYTOKINES IN SYSTEMIC SCLEROSIS PATIENTS  
M. Becker, M. Radic, K. Schmidt, D. Huscher, J. Günther, A. Kill, C. Meisel, E. Siegert, R. Ewert, G.-R. Burmester, G. Riemekasten
- PS173** B LYMPHOCYTE DEPLETION IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE AFTER TREATMENT WITH STANDARD AND LOW DOSES OF RITUXIMAB  
L. Ananjeva, A. Alexankin, O. Desinova, M. Starovojtova, A. Volkov, E. Alexandrova, E. Nasonov
- PS174** SMALL ANIMAL MRI FOR NON-INVASIVE LONGITUDINAL FOLLOW UP OF PULMONARY FIBROSIS IN MICE  
E. De Langhe, G. Vande Velde, T. Dresselaers, J. Poelmans, R. Lories, U. Himmelreich
- PS175** PULMONARY INVOLVEMENT IN SSC PATIENTS – A SINGLE CENTRE EXPERIENCE  
I. Dobrota, A. Petcu, S. Rednic
- PS176** USE OF IMMUNOSUPPRESSANTS IN SSC PATIENTS WITH INTERSTITIAL LUNG DISEASE – RESULTS OF THE DESSCIPHER PROJECT OF THE EUSTAR GROUP  
S. Adler, D. Huscher, Y. Allanore, L. Czirjak, F. Del Galdo, CP. Denton, O. Distler, M. Frerix, M. Matucci-Cerinic, U. Mueller-Ladner, I. Tarnar, G. Valentini, UA. Walker
- PS177** ALPHA2 (V) CHAIN AND COLVA2 INDUCES THE FIBRILLOGENESIS PROCESS IN DISTORTED LUNG FRAMEWORK OF SYSTEMIC SCLEROSIS  
P. Andrade, A.P.P. Velosa, J. Morais, M.P. Rangel, S. Carrasco, R.B. Chistmann, E.R. Parra, VL. Capelozzi, W.R. Teodoro
- PS178** EFFICACY AND SAFETY OF INTRAVENOUS CYCLOPHOSPHAMIDE IN SCLERODERMA LUNG DISEASE OF ELDERLY  
T. Nunokawa, N. Yokogawa, K. Shimada, S. Sugii
- PS179** PULMONARY ARTERIAL HYPERTENSION, CLASSIFICATION CRITERIA  
P. Carreira, L. Carmona, B. Joven, MJ. Ruiz Cano, P. Escribano, MA. Gomez-Sanchez

- PS180** EPOPROSTENOL RESCUE THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION AND IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION  
A.M. Roos, C.R. Pasarikovski, A. Kron, J.T. Granton, P. Lee, J. Thenganatt, S.R. Johnson
- PS181** SEX DISPARITIES IN SURVIVAL OF SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION AND IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION PATIENTS  
C.R. Pasarikovski, J.T. Granton, P. Lee, A.M. Roos, A.T. Kron, C. Chau, S.R. Johnson
- PS182** PROGNOSIS OF SYSTEMIC SCLEROSIS (SSC) PATIENTS WITH PULMONARY HYPERTENSION  
K. Takagi, Y. Kawaguchi, Y. Ota, T. Higuchi, H. Yamanaka
- PS183** SURVIVAL IN SSC-PAH BY SERUM AUTOANTIBODY STATUS  
M. Hinchcliff, S. Khanna, J. Lee, O. Almagor, RW. Chang, V. Steen, L. Chung
- PS184** THE SIGNIFICANCE OF A 'NORMAL DLCO' IN SCLERODERMA (PHAROS) COHORT  
T. Frech, M. Murtaugh, L. Shapiro, V. Steen
- PS185** UTILITY OF B-TYPE NATRIURETIC PEPTIDES IN THE ASSESSMENT OF PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY HYPERTENSION IN THE PHAROS REGISTRY  
L. Chung, D.E. Furst, S. Li, V.D. Steen, R.T. Zamanian
- PS186** THE DIFFERENCES, WHICH SEEM TO BE A PATHOPHYSIOLOGY OF PULMONARY HYPERTENSION, OF CAROTID DOPPLER AND ECHOCARDIOGRAPHIC FINDINGS IN EACH CONNECTIVE TISSUE DISEASE  
JH. Choi, SJ. Joo, J. Kim, EJ. Park
- PS187** SURVIVAL AT PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: SINGLE EXPERT CENTRE EXPERIENCE  
A. Volkov, N. Yudkina, E. Nikolaeva
- PS188** ECHOCARDIOGRAPHIC ALTERATIONS IN A SERIES OF PATIENTS WITH SYSTEMIC SYSTEMIC SCLEROSIS  
FJ. Garcia-Hernandez, R. Gonzalez-Leon, JE. Lopez-Haldon, E. Montero-Mateos, A. Leon-Guisado, I. Porras-Antras, C. Sotomayor-Lapiedra, ML. Artero-Gonzalez
- PS189** ELEVATED SERUM LEVELS OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AND STEM CELL GROWTH FACTOR BETA (SCGF BETA) IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)  
K. Stefanantoni, I. Sciarra, M. Vasile, R. Badagliacca, R. Poscia, M. Pendolino, C. Alessandri, C.D. Vizza, G. Valesini, V. Riccieri
- PS190** SOME DIFFERENCES BETWEEN CONNECTIVE TISSUE DISEASE-ASSOCIATED AND IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION AT THE TIME OF DIAGNOSIS  
M. Luknar, P. Lesny, J. Rovensky, E. Goncalvesova
- PS191** PULMONARY ARTERIAL HYPERTENSION IN A CONTEMPORARY DRUG REGISTRY: RESULTS OF THE VOLT STUDY, WITH AN EMPHASIS ON PAH ASSOCIATED WITH CONNECTIVE TISSUE DISEASE  
JL. Vachiéry, J. Langley, AJ. Peacock, O. Sitbon, N. Galie
- PS192** PREVALENCE OF PULMONARY HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS  
M. Salgado, L. Madeira, L. Theilacker, R. Silveira, R. Zandonade, S. Francisco, Z. Brito, F. Aguiar, L. D'Almeida, J. Vaz
- PS193** CARDIOTHORACIC RATIO IN CHEST RADIOGRAPHY MAY FORECAST THE OCCURRENCE OF PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS  
SW. Lee, SW. Yim, SY. Lee, WT. Chung
- PS194** EARLY PULMONARY HIPERTENSION AND EARLY PULMONARY FIBROSIS: HOW CAN I TREAT? AND WHO IS THE FIRST?  
R. Travassos Jr, E. Freire, C. Burity
- PS195** CLINICAL USEFULNESS OF MEASURING RED BLOOD CELL DISTRIBUTION WIDTH (RDW) IN PATIENTS WITH SYSTEMIC SCLEROSIS  
C. Varjú, N. Farkas, A. Szabó, V. Lóránd, D.P. Sarlós, T. Minier, Z. Prohászka, L. Czirkák

- PS196** **ARRHYTHMIAS AND HEART CONDUCTION DISTURBANCES IN PATIENTS WITH SCLEROSIS SYSTEMIC**  
R. Cimino, S. Giancotti, C. Pintaudi, S. Mazzuca
- PS197** **ECHOCARDIOGRAPHY OF THE RIGHT VENTRICLE IN PATIENT WITH SYSTEMIC SCLEROSIS AND RELATED CTD**  
J. Vymetal, M. Hutyra, A. Smrzova, P. Horak
- PS198** **ASYMPTOMATIC CARDIAC INVOLVEMENT IN THAI SYSTEMIC SCLEROSIS: PREVALENCE AND CLINICAL CORRELATION**  
C. Foocharoen, B. Pussadhamma, A. Mahakkanukrauh, S. Suwannaroj, R. Nanagara
- PS199** **CORRELATION BETWEEN CARDIAC MAGNETIC RESSONANCE IMAGING AND ECHOCARDIOGRAPHY IN SYSTEMIC SCLEROSIS**  
A. Fernández-Codina, C. Simeón, I. Pinal-Fernández, V. Pineda, MN. Pizzi, J. Rodríguez, J. Candell, V. Fonollosa, M. Vilardell
- PS200** **CHARACTERISATION OF SUB-CLINICAL PRIMARY MYOCARDIAL DISEASE IN SYSTEMIC SCLEROSIS - PRELIMINARY FINDINGS FROM A CARDIAC MAGNETIC RESONANCE AND ELECTROPHYSIOLOGICAL STUDY**  
L. Bissell, B. Erhayiem, J. P. Greenwood, F. Del Galdo, P. Emery, J. Andrews, S. Plein, M. H. Buch
- PS201** **SUBTLE IMPAIRMENT OF RIGHT VENTRICULAR FUNCTION IN SYSTEMIC SCLEROSIS WITH LUNG FIBROSIS DETECTED BY TISSUE DOPPLER**  
P. Sampaio-Barros, A.C. Rodrigues, M. Roque, A.L. Arruda, D. Becker, S. Barros, F. Kay, T. Emmerich, G. Cerri
- PS202** **CARDIAC TROPONIN T AND ANTI-CARDIAC TROPONIN I ANTIBODIES IN PATIENTS WITH SYSTEMIC SCLEROSIS: A MONOCENTRIC, RETROSPECTIVE PILOT STUDY**  
M. Vasile, Z. Kaya, M. Frerix, U. Mueller-Ladner, A. Rolf, F. MP. Meier
- PS203** **CARDIAC VALVE MORPHOLOGY AND LEFT VENTRICULAR FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND MATCHED POPULATION CONTROLS**  
A. Nordin, E. Svenungsson, L. Björnådal, K. Jensen-Urstad
- PS204** **PERICARDECTOMY ON CONSTRICTIVE PERICARDITIS AND DIFFUSE SYSTEMIC SCLEROSIS: FORTUITOUS ASSOCIATION?**  
T. Haddad, D. Hakem, A. Hamadene, N. Belabiod, M. Touati, R. Boughrarou, S. Ayat, B. Mansouri, SS. Salah, M. Bénidir, M.C. Abbadi, N. Ouadahi, A. Berrah
- PS205** **SERUM GROWTH DIFFERENTIATION FACTOR 15 AND TRANSFORMING GROWTH FACTOR BETA 1 IN PATIENTS WITH SYSTEMIC SCLEROSIS AND EARLY REMODELING OF THE CARDIOVASCULAR SYSTEM**  
E. Kucharz, K. Gieszczyk, A. Sikora-Puz, M. Mizia, M. Widuchowska, A. Kotulska, M. Kopec-Medrek, J. Chudek, K. Mizia-Stec
- PS206** **DESCRIPTIVE STUDY OF CARDIOVASCULAR RISK FACTORS AND ENDOTHELIAL DYSFUNCTION IN PATIENTS DIAGNOSED WITH SCLERODERMA AND MIXED CONNECTIVE TISSUE DISEASE**  
J. Gonzalez Martin, P. Garcia De La Peña Lefebvre, O. Carrion Otero, M. Valero Exposito, S. Rodriguez Rubio, I. Amil Casas, F. Aramburu Muñoz, F. Sainz Gonzalez
- PS207** **SCLERODERMA AND MYOCARDIAL INFARCTION: IS NOT FORTUITOUS ASSOCIATION!**  
N. Slimani, D. Hakem, Z. Benoui, A. Bouchemal, S. Lassouaoui, N. Ouadahi, A. Berrah
- PS208** **DATABASE ANALYSIS OF CARDIOVASCULAR RISK FACTORS IN 123 DANISH PATIENTS WITH SYSTEMIC SCLERODERMA**  
L. Iversen, HC. Ring, M. Mogensen
- PS209** **CAN SCORES FROM ENGLISH, FRENCH AND DUTCH VERSIONS OF THE FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY-FATIGUE (FACIT-F) BE POOLED? AN ASSESSMENT OF DIFFERENTIAL ITEM FUNCTIONING**  
L. Kwakkenbos, L. Willems, M. Baron, M. Hudson, CHM. van den Ende, B. Thombs, CSRG
- PS210** **ASSESSMENT OF SENSITIVITY TO CHANGE OF THE DISEASE ACTIVITY SCORE IN SYSTEMIC SCLEROSIS**  
S. Decuman, K. Melsens, F. De Keyser, Y. Piette, K. De Wilde, D. Elewaut, E. Deschepper, V. Smith

- PS211** **EXPLORING THE IMPACT OF FOOT DISABILITY IN SYSTEMIC SCLEROSIS**  
 B. Alcacer-Pitarch, A.C. Redmond, M.H. Buch, A.M. Keenan
- PS212** **TRANSITION OF CARE AND LONG-TERM OUTCOMES OF JUVENILE SYSTEMIC SCLEROSIS DURING ADULTHOOD: RESULTS FROM A FRENCH SINGLE-CENTER CASE-CONTROL STUDY**  
 F. Mauvais, B. Bader-Meunier, A. Berezne, G. Bussone, C. Bodemer, L. Guillevin, P. Quartier, L. Mouthon
- PS213** **IN SYSTEMIC SCLEROSIS, ANXIETY AND DEPRESSION, ASSESSED BY HOSPITAL ANXIETY DEPRESSION SCALE ARE INDEPENDENTLY ASSOCIATED WITH DISABILITY AND PSYCHOLOGICAL FACTORS**  
 A. Del Rosso, S. Mikhaylova, M. Baccini, I. Lupi, M. Matucci Cerinic, S. Maddali Bongio
- PS214** **SYSTEMIC SCLEROSIS DIAGNOSED IN ELDERLY: A FRENCH RETROSPECTIVE STUDY OF 27 PATIENTS**  
 A. Achille, O. Espitia, F. Perrin, C. Durant, A. Masseur, T. Ponge, J. Connault, A. Néel, MA. Pistorius, MA. Hamidou, C. Agard
- PS215** **ALEXITHYmia: UNSPEAKABLE SUFFERING, A PREVALENCE STUDY IN SYSTEMIC SCLEROSIS**  
 M. Vasile, I. Sciarra, K. Stefanantoni, N. Iannace, G. Valesini, V. Riccieri
- PS216** **ADHERENCE TO RECOMMENDATIONS FOR CERVICAL AND BREAST CANCER SCREENING IN SYSTEMIC SCLEROSIS**  
 P. Caramaschi, R. Vaccari, D. Biasi, C. Caimmi, S. Pieropan, I. Dal Forno, S. Adami
- PS217** **SURVIVAL PROGNOSTIC FACTORS AND CAUSE OF DEATH IN 213 IRANIAN PATIENTS WITH SYSTEMIC SCLEROSIS**  
 H. Poormoghim, N. Mojtাবে, A. Ghorbane, M. Moradi-Lake, S. Almacie, E. Elham Andalib
- PS218** **OCCUPATIONAL THERAPY IN SYSTEMIC SCLEROSIS. PRELIMINARY RESULTS OF A PILOT STUDY**  
 E. Pigatto, F. Rodeghiero, M. Rizzo, I. Benetton, P. Miatton, P. Polito, E. Zanatta, K. Bourji, A. Gava, L. Punzi, F. Cozzi
- PS219** **A SYSTEMATIC REVIEW ON THE DEVELOPMENT OF DISEASE ACTIVITY INDICES IN SYSTEMIC SCLEROSIS**  
 S. Decuman, K. Melsens, F. De Keyser, V. Smith
- PS220** **THE VALIDITY OF THE SATISFACTION WITH APPEARANCE SCALE AND THE BRIEF SATISFACTION WITH APPEARANCE SCALE FOR PATIENTS WITH LIMITED AND DIFFUSE SYSTEMIC SCLEROSIS**  
 V. Malcarne, R. Fox, S. Mills, S. Gholizadeh, E. Merz, P. Clements, S. Kafaja, D. Khanna, D. Furst
- PS221** **FIVE-YEAR SURVIVAL RATE AND PREDICTORS OF DEATH AND DISEASE WORSENING IN A SINGLE-CENTER COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
 A. Soare, C. Mihai, R. Dobrota, AM. Gherge, C. Vancea, M. Gorga, R. Ionitescu, R. Jurcut, S. Magda, T. Constantinescu, R. Sfrent-Cornateanu, A. Ciobotaru, I. Ancuta, M. Sasu, M. Milicescu, L. Macovei, C. Ciofu, A. Shorab, M. Bojinca, V. Stoica
- PS222** **TARGETING FEAR OF DISEASE PROGRESSION IN RHEUMATIC DISEASES: A CASE STUDY IN SYSTEMIC SCLEROSIS**  
 L. Kwakkenbos, L. Willems, F. van den Hoogen, H. Beenackers, T. Van Helmond, E. Becker, C. Van den Ende
- PS223** **CORRELATIONS BETWEEN LUNG INVOLVEMENT, QUALITY OF LIFE AND FUNCTIONAL DISABILITY IN PATIENTS WITH LIMITED SYSTEMIC SCLEROSIS**  
 F. Lumetti, L. Barone, C. Alfieri, N. Sverzellati, G. Delsante, A. Ariani
- PS224** **DEATH IN SYSTEMIC SCLEROSIS**  
 D. Hakem, A. Boudjelida, S. Lassouaoui, M. Ibrir-Khati, S. Medaoud, A. Hamadane, R. Yahiaoui, N. Slimani, N. Ouadahi, A. Berrah, R. Boughrrou, S. Ayat, B. Mansouri
- PS225** **QUALITY OF LIFE AND PSYCHOSOCIAL ASPECTS IN JUVENILE LOCALIZED SCLERODERMA: A CROSS-SECTIONAL STUDY IN 40 PATIENTS**  
 R. Culpò, M. Ricca, F. Vittadello, G. Sequi, F. Zulian, G. Martini

- PS226 MORTALITY IN SSC AND ITS ASSOCIATION WITH CLIMATE CONDITIONS – AN ANALYSIS BASED ON THE EUSTAR DATABASE**  
M. Langner, K. Scherber, M. Becker, EUSTAR Co-authors, W. Endlicher, G. Riemekasten
- PS227 THE IMPACT OF CIGARETTE SMOKING IN SYSTEMIC SCLEROSIS**  
B. Gundugdu, S. Yolbas, A. Yildirim, S. S. Koca
- PS228 CAUSES OF DEATH IN A COHORT OF ARGENTINE PATIENTS WITH SYSTEMIC SCLEROSIS**  
M. Scolnik, L. Catoggio, M. Sabelli, C. Saucedo, J. Marin, E. Soriano
- PS229 MOOD AND ANXIETY DISORDERS IN SYSTEMIC SCLEROSIS PATIENTS**  
A. Abdessemed, F. Benmoussa, N. Aitbelabas, F. Bougrina, S. Benchikh, N. Khaldoun, S. Haid, R. Chetouane, R. Djidjik, N. Brahimi, A. Ladjouze
- PS230 SCLERODERMIC PATIENTS: AN INTERDISCIPLINARY APPROACH**  
L. Lisi, E. Plessi, C. Scorolli, R. Meliconi, A. Rapaggi
- PS231 SYMPTOMS OF DEPRESSION AND ANXIETY IN CROATIAN PATIENTS WITH SYSTEMIC SCLEROSIS**  
R. Visevic, S. Rucevic, L. Maricic, V. Prus, J. Milas-Ahic, I. Kovacevic
- PS232 PROSPECTIVE ANALYSIS OF THE CLINICAL BURDEN OF LIMITED CUTANEOUS SYSTEMIC SCLEROSIS OVER 12 MONTHS**  
S. Nihtyanova, V. Ong, C. Denton
- PS233 RECOMMENDATIONS FOR FUTURE PATIENT FOCUSED TRIALS ADDRESSING FOOT PAIN IN SYSTEMIC SCLEROSIS**  
L. Loughrey, H. Collier
- PS234 ROLE OF NURSING IN THE PREVENTION OF SKIN ULCERS IN SSC: A PRELIMINARY STUDY**  
S. Gigli, L. Amanzi, L. Pedrocchio, C. Puccini, A. D'Ascanio, A. Della Rossa, S. Bombardieri
- PS235 SSC CLINICAL PROFILE OBSERVED IN A SINGLE INTERNAL MEDICINE DEPARTMENT**  
D. Hakem, A. Boudjelida, S. Lassouaoui, M. Ibrir, N. Slimani, R. Yahiaoui, Z. Benoui, M. Benidir, S.S. Salah, N. Ouadahi, A. Berrah
- PS236 NAILFOLD VIDEOCAPILLAROSCOPY FINDINGS IN SYSTEMIC SCLEROSIS AND PRIMARY RAYNAUD'S PHENOMENON – 12 MONTHS FOLLOW UP STUDY**  
P. Parmanne, A. Puhakka, T. Hasan, A. Häme, H. Mäkinen, J. Panelius, R. Peltomaa, M. Pertovaara, K.-L. Vidqvist, R. Luosujärvi
- PS237 UTILITY OF NAILFOLD CAPILLAROSCOPY FOR THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS**  
KX. Lim, HO. Thein, AHL. Low
- PS238 FINGER SKIN VASCULARIZATION IN PATIENTS WITH SYSTEMIC SCLEROSIS – COMPARISON OF ULTRASONOGRAPHY AND CAPILLAROSCOPY**  
S. Prodanovic, G. Radunovic, M. Zlatanovic, N. Damjanov, N. Gavrilov
- PS239 VIRTUAL TOUCH IMAGING AND QUANTIFICATION: A NEW NON-INVASIVE IMAGING METHOD TO MEASURE SKIN STIFFNESS FOR SCLERODERMA**  
T. Santiago, M.C. Coutinho, M.J. Salvador, F. Delgado, A.C. Redmond, J.A.P. Da Silva
- PS240 A STUDY COMPARING VIDEOCAPILLAROSCOPY AND DERMOSCOPY IN THE ASSESSMENT OF NAILFOLD CAPILLARIES IN PATIENTS WITH SYSTEMIC SCLEROSIS-SPECTRUM DISORDERS**  
M. Hughes, T. Moore, N. O'leary, A. Tracey, H. Ennis, G. Dinsdale, A. Murray, C. Roberts, A. Herrick
- PS241 LONGITUDINAL ASSESSMENT OF SCLERODERMA SKIN BY OPTICAL COHERENCE TOMOGRAPHY: PRELIMINARY VALIDATION OF SENSITIVITY TO CHANGE OVER-TIME**  
G. Abignano, L.A. Bissell, J. Britton, D. Woods, M. Buch, D. Mcgonagle, P. Emery, F. Del Galdo
- PS242 CONE BEAM CT SCAN IN THE MONITORING OF LINEAR SCLERODERMA OF THE FACE: PRELIMINARY RESULTS**  
C. Di Giovanni, S. Puggina, G. Martini, R. Culpò, F. Zulian
- PS243 NON-INVASIVE ASSESSMENT OF SILENT LIVER FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
A. Vacca, A. Civolani, A. Devigus, A. Floris, L. Fadda, G. Porru, P. Garau, V. Ibba, O. Sorbello, L. Demelia, A. Mathieu



- PS244** CHANGES IN THE THICKNESS AND STIFFNESS OF PALMO-PLANTAR SOFT TISSUES IN PEOPLE WITH SYSTEMIC SCLEROSIS  
T. Santiago, B. Alcacer-Pitarch, F. Del Galdo F, M.H. Buch, A.C. Redmond
- PS245** DO HEATING AND HYDRATION IMPROVE THE QUALITY OF NAILFOLD CAPILLAROSCOPY IMAGES?  
T. Moore, J. Wilkinson, I. Maciver, J. Manning, G. Dinsdale, A. Murray, A. Herrick
- PS246** VIDEO-CAPILLAROSCOPY OF PERI-CALCINOTIC SKIN INDICATES SPECIFIC FEATURES OF SEVERE MICRO-VASCULOPATHY ASSOCIATED WITH CALCIUM DEPOSITS IN SYSTEMIC SCLEROSIS  
L. Loughrey, LA. Bissell, A. Abignano, EMA. Hensor, M. Cutolo, A. Redmond, F. Del Galdo
- PS247** THYMIC FINDINGS BEFORE AND AFTER AUTOLOGEOUS STEM CELL TRANSPLANTATION FOR SEVERE SYSTEMIC SCLERODERMA – A RETROSPECTIVE STUDY USING COMPUTED TOMOGRAPHY IN THE PRE- AND POST-TRANSPLANTATION SETTING  
J. Henes, L. Kanz, M. Horger
- PS248** SCLERODERMA CAPILLAROSCOPIC PATTERNS IN AUTOIMMUNE DISEASES WITH RAYNAUD'S PHENOMENON. REPORT OF 100 PATIENTS  
R. Chetouane, F. Rahal, A. Abdessemed, A. Ladjouze-Rezig
- PS249** RELATIONSHIP BETWEEN ELASTONOSONOGRAPHY AND CAPILLAROSCOPIC PATTERNS IN SYSTEMIC SCLEROSIS  
R.D. Grembiale, C. Bruno, C. Tripolino, F. Ursini, M. Calabria, S. Mazzuca, S. Naty
- PS250** MUSCULOSKELETAL ULTRASONOGRAPHY FINDINGS IN SCLERODERMA PATIENTS  
N. Inanc, G. Ozen, P. Atagunduz, H. Direskeneli
- PS251** INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SINE SCLERODERMA SYSTEMIC SCLEROSIS: A CASE PRESENTATION  
I. Veltri, C. Bilder, A. Ditaranto, M. Mela, E. Baldessari, J. Caneva
- PS252** TOLERABILITY OF INTRAVENOUS PROSTANOID ILOPROST THROUGH ELASTOMERIC PUMP DEVICE IN SCLERODERMA PATIENTS  
G. De Marco, P. Tartaro, D. Riccoboni, M. Gazzola, V. Ferri, G. Semenzato, P. Ostuni, R. Marcolongo
- PS253** COMPARISON BETWEEN NORMAL INTRAVENOUS INFUSION AND INTRAVENOUS INFUSION THROUGH ELASTOMERIC PUMP OF ILOPROST: EVALUATION OF THE EFFECTIVENESS AND SIDE EFFECTS  
E. Bravi, E. Arrigoni, G. Crippa, A. Ariani, C. Concesi
- PS254** BIOLOGICAL THERAPY IN SYSTEMIC SCLEROSIS  
M. Castillo-Palma, R. Gonzalez-Leon, FJ. Garcia-Hernandez, E. Montero-Mateo, C. Sotomayor-Lapedara, A. Leon-Guisado, I. Porras-Antras, ML. Artero-Gonzalez
- PS255** ILOPROST AS CYCLIC SIX-DAY PER MONTH. LONG TERM EFFACACY IN SCLERODERMA PATIENTS  
R. Foti, G. Converso, A. Benenati, G. Amato, G D'Amico, N. Cino, A. Farina, M Di Gangi
- PS256** TOCILIZUMAB IN SYSTEMIC SCLEROSIS, A SINGLE CENTRE EXPERIENCE  
M. Saracco, E. Bellis, G. Rovera, R. Pellerito
- PS257** ALTERNATIVE BIOLOGICAL MODEL FOR PRECLINICAL TESTING  
I. Levacheva, O. Samsonova, Y. Rubtsov, V. Tkachuk, U. Bakowsky
- PS258** MACITENTAN IN THE TREATMENT OF DERMAL FIBROSIS IN PATIENTS AFFECTED BY LIMITED SYSTEMIC SCLEROSIS: IN VITRO EVIDENCES  
C. Corallo, G. Pecetti, M. Iglarz, A. Montella, R. Nuti, N. Giordano
- PS259** OPTIMIZED FORMULATION OF ENDOGENOUS NEUROPROTECTIVE AGENT  
I. Levacheva, E. Kanovalova, T. Fedorova, S. Stvolinskij, V. Koshelev, O. Samsonova, U. Bakowsky
- PS260** RAPID RESPONSE OF DIGITAL ULCERS TO BOSENTAN IN SYSTEMIC SCLEROSIS  
P. Athanassiou, I. Kostoglou-Athanassiou, D. Basdragianni, A. Papadaki
- PS261** SUCCESSFUL TREATMENT OF SYSTEMIC SCLEROSIS DIGITAL ULCERS WITH BOSENTAN  
P. Athanassiou, N. Kalaycheva

- PS262 SAFETY AND EFFECTIVENESS OF MYCOPHENOLATE IN SYSTEMIC SCLEROSIS: A SYSTEMIC REVIEW**  
M.A. Omair, A. Alahmadi, S.R. Johnson
- PS263 TREATMENT OF SYSTEMIC SCLEROSIS WITH TOCILIZUMAB**  
M. Fernandes das Neves, J. Caetano, F. Paula, M. Amaral, S. Oliveira, J. Delgado Alves
- PS264 IDENTIFICATION OF ICD-9 CODES ASSOCIATED WITH SCLERODERMA RENAL CRISIS**  
A. Valenzuela Vergara, A. Yaqub, D. Fiorentino, E. Krishnan, L. Chung
- PS265 INFORMATICS CAN IDENTIFY SYSTEMIC SCLEROSIS PATIENTS AT RISK FOR SCLERODERMA RENAL CRISIS**  
T. Frech, D. Redd, J. Rhiannon, M. Murtaugh, Q. Zeng
- PS266 JUVENILE SCLERODERMA: TREATMENT EXPERIENCE OF A SINGLE ONE CENTER**  
M.K. Osmirina, N.A. Geppè, J.O. Kostina, E.Y. Afonina, O.V. Shpitonkova
- PS267 SYSTEMIC SCLEROSIS AT THE CROSSROAD OF POLYAUTOIMMUNITY**  
M. Elhai, J. Avouac, A. Kahan, Y. Allanore
- PS268 CLINICAL AND SEROLOGICAL COMPARATIVE ANALYSIS OF SYSTEMIC SCLEROSIS WITH OR WITHOUT OVERLAP SYNDROMES IN A LARGE BRAZILIAN COHORT**  
C.M. Silva, S.G. Pasoto, V.S. Viana, L.P.C. Seguro, D.C.O. Andrade, E. Bonfá, P.D. Sampaio-Barros
- PS269 PREVALENCE OF A CHRONIC WIDESPREAD PAIN IN LOCALIZED AND DIFFUSE SYSTEMIC SCLEROSIS PATIENTS**  
S. Stisi, M. Orefice, S. Bellissimo, P. Sarzi-Puttini, F. Atzeni, C. Ricci, A. Batticciotto, G. Biasi, A. Gallo, R. Talotta, M.G. Ferrucci, M. Benucci, V. Di Sabatino
- PS270 SERUM ADROPIN LEVEL AND ENHO EXPRESSION IN SYSTEMIC SCLEROSIS**  
S. Yolbas, M. Kara, M. Yilmaz, S. Aydin, S. S. Koca
- PS271 PREVALENCE AND PREDICTIVE VALUE OF SCLERODERMA-SPECIFIC SERUM AUTOANTIBODIES IN THE GENERAL POPULATION OF A NORTHERN ITALIAN AREA**  
C. Selmi, F. Alborghetti, S. Pfeiffer, G. Colloredo, M.I.S. Achenza, F. Cavaciocchi, V. Paleari, M. De Santis, M.S. Massarotti, A. Ceribelli, F. Meda, A. Laria, L. Porra, P. Invernizzi, M. Torsten, P.L. Meroni
- PS272 OSTEOPOROSIS AND FRACTURE RISK IN OUTPATIENTS WITH SYSTEMIC SCLEROSIS**  
V. Codullo, F. Inverardi, S. Breda, L. Bogliolo, F. De Nard, G. Cagnotto, R. Caporali, C. Montecucco
- PS273 ARE THERE DIFFERENCES IN LIMITED SSC ACCORDING TO EXTENSION OF SKIN INVOLVEMENT?**  
M. Scolnik, E. Lancioni, L.J. Catoggio, M. Sabelli, Z. Bedran, C. Saucedo, J. Marin, ER. Soriano
- PS274 CORRELATION AMONG WHOLE BLOOD VISCOSITY, HEMATOCRIT AND CAPILLAROSCOPIC PATTERNS IN SYSTEMIC SCLEROSIS**  
C. Bruno, C. Tripolino, S. Mazzuca, F. Ursini, M. Calabria, S. Naty, R.D. Grembiale
- PS275 AUTOANTIBODIES IN SYSTEMIC SCLEROSIS MAY PREDICT DISEASE SEVERITY, COMPLICATIONS, AND MORTALITY: A SINGLE EUSTAR CENTER (042) EXPERIENCE**  
A. Balbir-Gurman, Y. Braun-Moscovici
- PS276 SSC-OVERLAP SYNDROMES: A DISTINCT CLINICAL SUBGROUP WITH SIGNIFICANT DIFFERENCES IN DISEASE PROGRESSION COMPARED TO LSSC AND DSSC PATIENTS**  
P. Moinzadeh, E. Aberer, K. Ahmadi-Simab, N. Blank, J.H.W. Distler, G. Fierlbeck, E. Genth, C. Guenther, R. Hein, J. Henes, L. Herich, I. Hergott, I. Koetter, A. Kreuter, T. Krieg, K. Kuhr, H.-M. Lorenz, F. Meier, I. Melchers, H. Mensing
- PS277 SYSTEMIC SCLEROSIS-RELATED AUTO-ANTIBODIES ARE MARKERS OF NEW CLINICAL ASSOCIATIONS IN A COHORT OF 328 BRAZILIAN PATIENTS**  
C.M. Silva, A.B. Bortoluzzo, V.S. Viana, S.G. Pasoto, E.P. Leon, E. Bonfá, P.D. Sampaio-Barros

- PS278 THE AUTOANTIBODY PROFILE OF THE WAIKATO HOSPITAL SYSTEMIC SCLEROSIS COHORT (WHSSC COHORT)**  
W. Chang, A. Schollum, R. Campbell, T. Sole, J. Petrie, M. Empson, D. White, K. Solanki
- PS279 HIGH PREVALENCE OF ANTI-THYROID ANTIBODIES IN A NEW ZEALAND COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
K. Solanki, M. Al-Majmoei, A. Schollum, T. Sole, J. Petrie, D. White
- PS280 LOW DOSE MODIFIED-RELEASE PREDNISONE TREATMENT AND A THERAPIST-GUIDED EXERCISE PROGRAM IN UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE PATIENTS: OUR 24-MONTH RESULTS**  
C. Marrese, A. Izzo, P. Dell'Aia, G. Sanseverino, E. Bove, C. Riccioni
- PS281 NEUTROPHIL-LYMPHOCYTE AND PLATELET-LYMPHOCYTE RATIOS IN SYSTEMIC SCLEROSIS**  
S. Yolbas, B. Gundugdu, A. Yildirim, S. S. Koca
- PS282 COEXISTENCE OF ANTITOPISOMERASE I AND ANTICENTROMERE ANTIBODIES IN 3 PATIENTS WITH SYSTEMIC SCLEROSIS**  
C. Valette, A. Fauconneau, C. Bordes, C. Combes, C. Dromer, J. Constans, B. Seguy, E. Lazaro, MS. Doutré
- PS283 EFFECTS OF ILOPROST ON T-LYMPHOCYTE ACTIVATION PATHWAY IN EARLY SYSTEMIC SCLEROSIS (ESSC)**  
P. Faggioli, A. Gatti, A. Mazzone, A. Sciascera, B. Brando
- PS284 DISTRIBUTION OF BODY MASS INDEX AND METABOLIC SYNDROME IN PATIENTS WITH SYSTEMIC SCLEROSIS: STUDY OF A SINGLE ITALIAN CENTRE**  
G. De Luca, SL. Bosello, G. Berardi, M. Rucco, G. Canestrari, M. Correrà, A. Capacci, F. Parisi, E. Gremese, G. Ferraccioli
- PS285 COMPROMISE OF FOREARM BONE MASS IN PATIENTS WITH SYSTEMIC SCLEROSIS: ASSOCIATION WITH DISEASE DURATION, RANGE OF MOTION, QUALITY OF LIFE AND SYSTEMIC BONE INVOLVEMENT**  
P. Sampaio-Barros, M. Sampaio-Barros, L. Takayama, J. Couto, V. Caparbo, R.M. Pereira
- PS286 LEVELS OF VITAMIN D, PTH AND CALCIUM IN PATIENTS WITH SYSTEMIC SCLEROSIS IN LIMITED AND DIFFUSE FORMS**  
M. Salgado, R. Silveira, L. Theilacker, R. Zandonade, S. Francisco, Z. Brito, F. Aguiar, L. D'Almeida, J. Vaz
- PS287 BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
R. Alekperov, A. Smirnov, N. Toroptsova, E. Cheryemurhina
- PS288 BONE MICROARCHITECTURE ASSESSMENT BY TRABECULAR BONE SCORE, IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
K. Simic Pasalic, N. Damjanov, G. Marinkovic
- PS289 SEXUAL DYSFUNCTION AND LOWER URINARY TRACT SYMPTOMS IN 74 PATIENTS WITH SYSTEMIC SCLEROSIS**  
K. Sanchez Barrueto, P. Denys, F. Giuliano, C. Palazzo, A. Berezne, H. Abid, F. Rannou, S. Poiraudreau, L. Mouthon
- PS290 ANTI-NUCLEAR AUTOANTIBODIES IN 200 IRANIAN PATIENTS WITH SYSTEMIC SCLEROSIS: CORRELATION WITH CHARACTERISTIC CLINICAL FEATURES**  
H. Poormoghim, N. Mojtavavi, A.s. Ghorbannia, M. Moradi-Lake, B. Asadifar, M. Ghelman, S. Almacie, E. Andalib
- PS291 SEVERITY OF NAILFOLD CAPILLARY MICROSCOPY CORRELATE WITH BONE MINERAL DENSITOMETRY BY ULTRASONOGRAPHY AND RODNAN SKIN SCORE IN SSC PATIENTS**  
R. Cimino, C. Pintaudi, S. Giancotti, S. Mazzuca
- PS292 CALCINOSIS PREFERENTIALLY AFFECTS THE THUMB COMPARED TO OTHER FINGERS IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
R. Gauhar, J. Wilkinson, J. Harris, J. Manning, A. Herrick
- PS293 SMOKING AND ITS EFFECT ON SKIN OF PATIENTS WITH SYSTEMIC SCLEROSIS**  
R. López Martínez, J. Pretini, D. Vera Alarcón, A. Villacreces Arteaga, V. Cosentino, S. Montoya, E. Kerzberg

- PS294** CORRELATION BETWEEN CHRONIC WIDESPREAD PAIN OR FIBROMYALGIA AND ACTH AXIS ALTERATIONS IN PATIENTS WITH LOCALISED AND DIFFUSE SYSTEMIC SCLEROSIS  
R. Talotta, F. Matucci, M. Benucci, F. Li Gobbi, M. Manfredi, M. Infantino, G. Baldi, T. Vago, S. Stisi, P. Sarzi-Puttini, F. Atzeni
- PS295** INFLUENCE OF GENDER, ETHNICITY AND AGE AT ONSET IN THE CLINICAL PRESENTATION OF SYSTEMIC SCLEROSIS IN A LARGE BRAZILIAN COHORT OF 1017 PATIENTS  
P. Sampaio-Barros, R. Marangoni, L. Rocha, A. Bortoluzzo, L. Seguro, A.P. Del Rio, D. Andrade, I. Nascimento, A.L. Foelkel, J.F. Marques-Neto
- PS296** ARTERIAL STIFFNESS IN SSC PATIENTS- A SINGLE CENTRE EXPERIENCE  
A. Petcu, M. Rinzis, A. Albu, S. Rednic
- PS297** JUVENILE SCLERODERMA INTERNATIONAL NETWORK (JUSINET) DATABASE: A RELIABLE INSTRUMENT FOR CLINICAL RESEARCH IN JUVENILE SCLERODERMA SYNDROMES  
G. Cuffaro, G. Martini, F. Sperotto, T. Avcin, R. Russo, O. Kasapcopur, F. Vittadello, F. Zulian
- PS298** MODIFIED RODNAN SKIN SCORE: A NEW TECHNOLOGICAL APPROACH  
S. Parisi, M. Scarati, M. Priora, M. Bruzzone, E. Fusaro
- PS299** SIGNIFICANCE OF IGG LEVELS IN THE WAIKATO HOSPITAL SYSTEMIC SCLEROSIS COHORT  
K. Ip, A. Schollum, J. Petrie, T. Sole, D. White, K. Solanki
- PS300** SEVERE VITAMIN D DEFICIENCY IN SYSTEMIC SCLEROSIS  
F. Lumetti, D. Giuggioli, A. Spinella, F. Campomori, A. Manfredi, C. Ferri
- PS301** ENVIRONMENTAL FACTORS AND INDUCTION OF SYSTEMIC SCLEROSIS: ANALYSIS OF 211 CONSECUTIVE PATIENTS  
P. Sampaio-Barros, L. Aquila, A.C. Medeiros, L. Seguro, D. Andrade
- PS302** UTILITY OF THE 6 MINUTE WALKING TEST IN SYSTEMIC SCLEROSIS, EXPERIENCE FROM 20 CROATIAN PATIENTS  
R. Visevic, L. Maricic, S. Rucevic, V. Prus, J. Milas-Ahic, I. Kovacevic
- PS303** PARTICULARITIES OF SCLERODERMA IN MALE PATIENTS  
S. Lassouaoui, D. Hakem, N. Ouadahi, A. Boudelida, A. Berrah
- PS304** CLINICAL UTILITY OF SALT & PEPPER SKIN CHANGES IN THE WAIKATO HOSPITAL SYSTEMIC SCLEROSIS COHORT  
K. Solanki, C. Hor, A. Schollum, R. Campbell, M. Empson, T. Sole, J. Petrie, D. White
- PS305** MUSCULAR INVOLVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS: MYOSITIS RELATED TO SSC OR TO OTHER AUTOIMMUNE DISEASE?  
T. Ben Salem, M. Maiza, A. Hamzaoui, M. Khanfir, I. Ben Ghorbel, M. Lamloum, M.H. Houman
- PS306** PERIPHERAL NEUROPATHY IN SYSTEMIC SCLEROSIS PATIENTS: A PILOT STUDY  
M. Radic, D. Vucina, D. Martinovic Kaliterna, J. Radic, D. Perkovic
- PS307** PROTECTIVE EFFECTS OF SUPPLEMENTATION WITH 25-HYDROXYVITAMIN D AND AN INDIVIDUALIZED REHABILITATION PROGRAM IN SYSTEMIC SCLEROSIS PATIENTS: OUR 2-YEAR EXPERIENCE  
C. Marrese, A. Izzo, P. Dell'Aia, E. Bove, E. Grimaldi, C. Riccioni
- PS308** JOINT INVOLVEMENT IN SYSTEMIC SCLEROSIS AND ITS RELATIONSHIP WITH AUTOANTIBODY TO ANTI-CYCLIC CITRULLINATED PEPTIDE  
A. Abdessemed, N. Khaldoun, A. Tahiat, R. Djidjik, Y. Mellal, I. Allam, S. Slimani, A. Haddouche, D. Hakem, N. Brahimi, A. Berrah, M. Ghaffor, A. Ladjouze
- PS309** 22 YEARS EXPERIENCE OF PATIENTS WITH SYSTEMIC SCLEROSIS ON HOME PARENTERAL NUTRITION  
E. Harrison, A.L. Herrick, J.T. McLaughlin, S. Lal

- PS310** **ESOPHAGEAL INVOLVEMENT IN SYSTEMIC SCLEROSIS: CLINICAL CORRELATIONS**  
M. Lara, M. Rivero, N. Aldabe, R. Ramos, G. Salis, F. Zazzetti, J. Romero, M. Khoury, L. Colombato, J. Barreira
- PS311** **COMPARISON OF MID UPPER ARM ANTHROPOMETRY TO BODY MASS INDEX IN PATIENTS WITH SYSTEMIC SCLEROSIS**  
E. Harrison, A.L. Herrick, J.T. McLaughlin, S. Lal
- PS312** **OBESITY: A NEW ASPETC OF MALNUTRITION IN SYSTEMIC SCLEROSIS**  
R. Carignola, V. Data, E. Montabone
- PS313** **ASSESSMENT OF VALIDITY OF GASTROINTESTINAL MOTILITY PROCEDURES USED IN SYSTEMIC SCLEROSIS, BASED ON OMERACT CRITERIA**  
Y. Braun-Moscovici, M. Braun, D. Khanna, A. Balbir-Gurman, D.E. Furst
- PS314** **ESOPHAGEAL ABNORMALITIES IN VERY EARLY SYSTEMIC SCLEROSIS. A CASE SERIES**  
I. Veltri, D. Bruno, M. Mela, A. Ditaranto, E. Baldessari, C. Bilder
- PS315** **SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH SYSTEMIC SCLEROSIS, CLINICAL DATA RELEVANCE**  
T. Soukup, J. Cyraný, M. Kopacova, I. Tacheci, J. Bures
- PS316** **SYSTEMATIC EVALUATION OF ESOPHAGEAL AND ANORECTAL DAMAGE IN SYSTEMIC SCLEROSIS : PRELIMINARY RESULTS**  
L. Luciano, E. Bernit, K. Mazodier, V. Veit, L. Chiche, M. Ebbo, J. Rodolphe, J-M. Durand, N. Schleinitz, G. Kaplanski, J-R. Harle, J-C. Grimaud, V. Vitton
- PS317** **TRANSLATION, CROSS-CULTURAL ADAPTATION, AND VALIDATION OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES SCLERODERMA CLINICAL TRIAL CONSORTIUM GASTROINTESTINAL TRACT INSTRUMENT 2.0 INTO THE DUTCH LANGUAGE**  
J. Meijs, D. Pors, T. Vliet-Vlieland, T. Huizinga, A. Schouffoer
- PS318** **GIT MANIFESTATIONS OF SYSTEMIC SCLEROSIS AS THE MOST FREQUENT. IS IT THE MOST IRRITANT TOO?**  
N. Fathi, H. Imam, D. Hammady, M. Abdlaziz, H. Abozaid
- PS319** **CHARACTERIZATION OF SYSTEMIC SCLEROSIS PATIENTS FOLLOWED IN A SYSTEMIC IMMUNE MEDIATED DISEASES CLINIC - 4 YEAR RETROSPECTIVE ANALYSIS**  
J. Caetano, F. Paula, M. Amaral, S. Oliveira, J. Delgado Alves
- PS320** **CHARACTERIZATION OF INTERSTITIAL LUNG DISEASE IN A COHORT OF SYSTEMIC SCLEROSIS PATIENTS - 4 YEAR FOLLOW-UP DATA**  
F. Paula, J. Caetano, M. Amaral, S. Oliveira, J. Delgado Alves
- PS321** **THE TYROSINE KINASE INHIBITOR DASATINIB EFFICIENTLY BLOCKS PDGF-INDUCED ORBITAL FIBROBLAST ACTIVATION: A POTENTIAL NOVEL THERAPEUTIC AGENT IN FIBROTIC DISEASE?**  
S. Virakul, V.A.S.H. Dalm, D. Paridaens, W.A. van den Bosch, N. Hirankarn, P.M. Van Hagen, W.A. Dik
- PS322** **UPDATE ON THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT. [WWW.JUVENILESCLERODERMA.COM](http://WWW.JUVENILESCLERODERMA.COM)**  
I. Foeldvari, A. Wierk, T. Avcin, J. Brunner, R. Cimaz, T. Kallinich, M. Katsicas, y. Uziel, M. Kostic, T. Terreri, D. Nemcova, J. Mueller, F. Sztajn bok, K. Minden, I. Kone-Paut
- PS323** **SYSTEMIC SCLEROSIS IN OVERLAP WITH RHEUMATOID ARTHRITIS: A RATHER FREQUENT ASSOCIATION IN SCLERODERMA PATIENTS**  
C. Mihai, R. Dobrota, A. Soare, AM. Gherghe, DL. Constantin, M. Gorga, RC. Ionitescu, M. Bojinca, V. Stoica
- PS324** **EVOLUTION OF SYSTEMIC SCLEROSIS OVERLAP SYNDROME**  
O. Desinova, M. Starovoytova, L. Ananieva, N. Guseva
- PS325** **ASSOCIATION BETWEEN SYSTEMIC SCLEROSIS AND SJÖGREN'S SYNDROME**  
T. Ben Salem, A. El Ouni, M. Khanfir, A. Hamzaoui, M. Lamloum, I. Ben Ghorbel, MH. Houman

- PS326** SJOGRENS SYNDROME IN SYSTEMIC SCLEROSIS  
S. Agachi, L. Groppa, S. Popa
- PS327** EFFECT OF AMBRISENTAN ON DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A CASE REPORT  
V. Tomaselli, D. D'Ambrosio, L. Massarelli, D. Roccatello
- PS328** IMPROVEMENT OF PULMONARY FUNCTION IN A PATIENT WITH INTERSTITIAL LUNG DISEASE SECONDARY TO SYSTEMIC SCLEROSIS AFTER TREATMENT WITH TOCILIZUMAB  
A. Severino, B. Vigone, L. Beretta
- PS329** CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC SCLEROSIS- A RARE ASSOCIATION  
A. Petcu, M. Rinzis, S. Rednic
- PS330** SYSTEMIC SCLEROSIS WITH SYSTEMIC LYMPHADENOPATHY COMPLICATED BY ADENOCARCINOMA PROSTATE AND TUBERCULOSIS  
E. Morgiel, M. Madej, P. Wiland
- PS331** SUCCESSFUL TREATMENT OF MEDICALLY REFRACTORY SCLERODERMA DIGITAL GANGRENE WITH LONGTERM CONTINUOUS BRACHIAL PLEXUS BLOCK  
A. Marcocchia, C. Salvucci, G. Caravelli, A. Ciani, G.M. De Matteis, M. Di Carlo, M. Bosco, P. Mazzini
- PS332** A CASE OF LONG-STANDING LIMITED CUTANEOUS SCLERODERMA WITH CHRONIC INFECTION – DIAGNOSTIC CHALLENGES  
S. Lambova, L. Sapundzhiev
- PS333** COMPLEX PATHOPHYSIOLOGY OF PULMONARY HYPERTENSION ASSOCIATED WITH SYSTEMIC SCLEROSIS: MERITS AND DEMERITS OF AGGRESSIVE TREATMENT WITH PULMONARY VASODILATORS  
M. Kuwana, Y. Tamura
- PS334** COEXISTENCE OF SYSTEMIC SCLEROSIS AND SARCOIDOSIS: A CASE REPORT  
S. Kobak, F. Sever, O. Sivrikoz
- PS335** RENAL THROMBOTIC MICROANGIOPATHY TRIGGERED BY LUNG CANCER IN LIMITED SSC-A CASE REPORT-  
T. Kise, N. Yokogawa, K. Shimada, S. Sugii
- PS336** PRIMITIVE HEART DISEASES IN SYSTEMIC SCLEROSIS : REVIEW OF 05 CASES  
D. Hakem, M. Ibrir, S. Lassouaoui, R. Boughrarou, S. Ayat, N. Ouadahi, B. Mansouri, A. Berrah
- PS337** DIGITAL NECROSIS IN SYSTEMIC SCLEROSIS NOT ONLY A MICROVASCULAR DISEASE: A CASE REPORT  
A. Spinella, D. Giuggioli, A. Manfredi, F. Lumetti, F. Campomori, C. Ferri
- PS338** SCLERODERMA MODEL OF CARE – TEAM MEETINGS  
B. Gemmell, C. Page, H. O'Sullivan
- PS339** A PARTICULAR CASE OF SEVERE SYSTEMIC SCLEROSIS, PROCEEDED BY BULLOUS MANIFESTATIONS IN APPARENTLY QUIESCENT SCLERODERMA  
R. Colia, A. Marucci, V. Di Bello, A. Gaudio, F.P. Cantatore
- PS340** THYROID DYSORDERS IN PATIENTS WITH SYSTEMIC SCLEROSIS: BIOCHEMICAL AND SONOGRAPHIC CHARACTERISTICS  
P. Rotman-Pikielny, M. Werner, Y. Levy
- PS341** EXERCISE TRAINING IN SYSTEMIC SCLEROSIS – FIVE SSC PATIENTS FINISHED THE BERLIN MARATHON  
M. Buslau, M. Müller, A. Gösele, Th. Ettl
- PS342** SYSTEMIC SCLEROSIS ASSOCIATED TO SYSTEMIC LUPUS ERYTHEMATOSUS  
T. Ben Salem, H. Heriz, N. Belfeki, A. Hamzaoui, M. Khanfir, I. Ben Ghorbel, M. Lamloum, MH. Houman
- PS343** BK VIRUS ASSOCIATED HAEMORRHAGIC CYSTITIS IN A SCLERODERMA PATIENT AFTER CYCLOPHOSPHAMIDE THERAPY  
A. Belotti Masserini, PL. Colombelli, S. Panza, G. Dognini, F. Cagnoni, C. Mastaglio, M. Destro

- PS344** SPECIFIC ATROPHY OF THE VOCAL FOLD DURING SCLERODERMA: UNDERESTIMED IMPACT ON QUALITY OF LIFE, ABOUT 2 CASES  
P. Belénotti, A. Lagier, A. Benyamine, B. Granel, J. Serratrice, A. Giovanni, P.J. Weiller
- PS345** RITUXIMAB TREATMENT IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: A CASE REPORT  
M.G. Santiago, T. Santiago, M. Rodrigues, C. Costa, P. Carvalho, J. Ferreira, S. Serra, M.J. Salvador, J.A.P. Da Silva
- PS346** SPARING EFFECT OF HEMIPLEGIA ON SCLERODERMA-LIKE MICROVASCULAR INVOLVEMENT AND SKIN FIBROSIS: A CASE REPORT  
N. Ughi, F. Ingegnoli, R. Gualtierotti, S. Zeni
- PS347** A RARE CASE OF CHRONIC EFFUSIVE-CONSTRICTIVE PERICARDITIS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS  
K. Solanki, S. Pasupati, I. Ternouth
- PS348** A RARE PRESENTATION OF SCLERODERMA RENAL CRISIS FOLLOWING SILICONE BREAST IMPLANT RUPTURE  
G. Al Aranjí, D. White, K. Solanki
- PS349** A CASE OF SYSTEMIC SCLEROSIS PATIENT THAT HAD SEVERE HYPOTENSION WITH ACUTE RENAL FAILURE DUE TO THE SILDENAFIL  
S. Nah, S. Jung, J. Jeon, H. Kim
- PS350** SYSTEMIC SCLEROSIS WITH EXTENT NECROSIS AND LOST OF PART OF THE FOOT- A CASE REPORT  
M. Salgado, L. Theilacker, R. Silveira, R. Zandonade, Z. Brito, S. Francisco, F. Aguiar, G. Aredes, J. Vaz, L. D'Almeida
- PS351** AN ALTERNATIVE APPROACH TO THE MANAGEMENT OF A PATIENT WITH SSC-MYOSITIS ASSOCIATED WITH DYSPHAGIA  
M. Hughes, E. Harrison, P. Paine, A. Herrick
- PS352** A MULTI-DISCIPLINARY APPROACH TO THE MANAGEMENT OF A PATIENT WITH RAPIDLY PROGRESSIVE SSC, SEVERE GASTROINTESTINAL INVOLVEMENT AND MALNUTRITION  
M. Hughes, E. Harrison, P. Paine, A. Herrick
- PS353** ANGIOSARCOMA OF THE SCALP IN A PATIENT WITH SYSTEMIC SCLEROSIS  
Y. Fujisawa, Y. Nakamura, Y. Kawachi, M. Fujimoto
- PS354** WHEN DOES SYSTEMIC SCLEROSIS IN CHILDHOOD REALLY START? AN ORIGINAL CASE REPORT  
C. Culpo, M. Cappella, G. Martini, F. Zulian
- PS355** A RARE PRESENTATION OF NECK PAIN WITH RADICULOPATHY IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS  
K. Solanki, W. Chang, A. Schollum, Z. Hussain
- PS356** CONVINCING EFFECT OF BOTULINUM TOXIN A TO TREATMENT RESISTANT DIGITAL ULCERS ON TOES IN A PATIENT WITH SYSTEMIC SCLEROSIS. A CASE  
J. Baumgartner-Nielsen, A. Braae Olesen

# GENERAL INFORMATION

## Congress Venue

### Ergife Palace Hotel & Conference Center

Via Aurelia 619 – 00165 Rome, Italy  
Telephone: +39 06 66441  
www.ergifepalacehotel.com

## How to reach the Congress Venue

### By car

From motorway A1, A12 or A24, take the “Grande Raccordo Anulare”, exit 1 “Aurelia” in direction “Roma Centro Vaticano”. Then follow Via Aurelia until number 619.

### By train/subway

From railway station “Termini” take the subway - line A, direction “Battistini” until “Cornelia” stop. Follow exit “P.zza Irnerio” and then “Via Aurelia”. Then take the bus no. 246 and get off after two stops.

### By plane

From the Rome international airport “Leonardo da Vinci” in Fiumicino, take the train “Leonardo Express” until the railways station “Termini” and then follow the indications here above.

## Organizing Secretariat

AIM Group International  
Florence Office  
Viale G. Mazzini, 70 - 50132 Florence  
tel 055 233881 - fax 055 2480246  
ssc2012@aimgroup.eu  
www.sscworldcongress.org

Onsite the Registration Desk will be open for participants at the following times: *Thursday, February 6* from 11:30 to 20:00, *Friday, February 7* from 07:30 to 18:00 and *Saturday, February 8* from 07:30 to 13:30

## REGISTRATION FEE (VAT incl.)

Physicians	€ 794,00
PhD/Young Investigators* / Fellows	€ 342,00
HP	€ 342,00
Medical Students**	€ 220,00
Patients	€ 35,00

\* For young doctors under 30 years of age. Copy of the ID or passport is requested.

\*\* These individuals must include a letter from their program director, chief of service or faculty advisor to be eligible for reduced fees.

## Registration fees include:

Congress kit, access to the scientific sessions, admission to the exhibition and poster area, certificate of attendance, coffee breaks and working lunch as indicated in the programme, abstracts book in the USB pendrive and online subscription for one year to “Clinical and Experimental Rheumatology – Clinical and Experimental Scleroderma”.

## Registration fee for patients includes:

Congress kit, access to the Opening Ceremony of the medical congress, scientific sessions of the patient congress only, coffee breaks and working lunch as indicated in the patient program.



## Congress badges

Each participant may collect the badge at the registration desk. Participants are kindly requested to wear their badge during all congress activities and social events.

No colour:	Participant
Red colour:	Speakers and Chairpersons
Yellow colour:	Exhibitors and Sponsors
Blue colour:	Patients

## Internet connection

Free wi-fi connection is available in all congress spaces. No password is requested.

## Language

The official language is English.

## Catering

### Coffee breaks

Coffee breaks will be organized in the exhibition area, Level -2 during the following times:

<i>Friday, February 7</i>	from 10:10 to 10:30 and from 16:40 to 16:55
<i>Saturday, February 8</i>	from 10:30 to 10:45

## Lunch

A standing buffet lunch will be offered to all registered participants on *Friday, February 7* from 13,30 to 14:30 in the exhibition area, level -2.


## Certificate of Attendance

Certificates of attendance will be available on request starting from *Saturday, February 8* at the Registration desk.

## Exhibition

An exhibition will be open in the following days at level -2: *Thursday, February 6* from 15:00 to 19:00, *Friday, February 7* from 08:30 to 18:00, *Saturday, February 8* from 08:30 to 13:30.

## Exhibition Floorplan



- 1 – General Electric
- 2 – Esaote
- 3,4 – Cytori
- 5 – Fidia Farmaceutici

- 7 – GlaxoSmithKline
- 8 – DS Medica
- 9 – EUSTAR/DeSSciper project
- 10 - Actelion

## Social Programme

### Welcome Cocktail – Thursday, February 6

A light welcome cocktail will be held after the Opening Ceremony in the lobby of the hotel, in the bar area for all registered participants.

### Congress Dinner – Friday, February 7

A seated Congress Dinner will be held at Palazzo Brancaccio in Viale del Monte Oppio 7. Transfer by bus will be provided from the hotel Ergife at 19:30. The dinner will start at 20:00. Limited number of participants. Reservations are accepted on a “first come first served” basis. Remaining tickets will be sold at the “New registration” desk until *Friday, February 7* at 10:00.

# SCIENTIFIC INFORMATION



## Abstract Sessions

Selected papers will be orally presented by the Authors. Authors have the time indicated in the programme including the discussion.

## Poster Session & Poster tours

### Posters Session

Poster session will take place in the Poster Area at the ground floor. Authors have been given a number and must be fixed on the poster board marked with the same number. Posters must be hanged on *Friday, February 7* from 08:00 to 09:00 for display and removed within 13:30 on *Saturday, February 8*. Poster size must be cm. 90 (width) x cm. 150 (height) and the format must be VERTICAL.

### Poster tours

Tours will take place in the Poster Area at the ground floor on *Friday, February 7* from 11:00 to 12:00. Participants who made the pre-registration to the poster tours are kindly requested to gather at 10.50 in front of the entrance of the Poster Area, in the meeting point indicated with the number of the tour, to join their leader and start at 11:00 the tour. Posters selected for the poster tours are indicated in the scientific program.

For both poster sessions and poster tours on *Friday, February 7* authors are kindly asked to stand by their poster at 11:00 either for discussion with delegates or for discussion during the poster tour. *Saturday, February 8* posters can be left in the Poster Area for the whole morning until 13:30.

## Meet the Professors session

Meet the Professors sessions will be organized on *Saturday, February 8* from 08:00 to 09:00 (see the scientific program) for young practicing physicians only, for a maximum of 15 participants each, on first come, first served basis. Remaining places can be booked at the "New registration" desk.

## Slide Center

The Slide Center is available in the **GERASA ROOM** at level -2. Speakers are requested to load their slides in the Slide Center at least three hours before their presentation (or, if their session starts at 8:00, by 18:00 on the previous day). The opening hours of the slide center are: *Thursday, February 6*, from 12:00 to 19:30, *Friday, February 7* from 07:30 to 17:00 and *Saturday, February 8*, from 07:30 to 13:00.

## Abstract book

The abstracts of the oral presentations and posters are included in the USB pendrive in the congress bag

The Congress Organisers gratefully acknowledge support received from all exhibitors and the following sponsors:

### Platinum Sponsor

---



### Gold Sponsor

---



### Silver Sponsor

---



### Bronze Sponsors

---



The patient congress is supported by:



Organizing Secretariat



**AIM Group International**

Florence Office

Viale G. Mazzini, 70

50132 Florence, Italy

ph. +39 055 233881

fax +39 055 2480246

ssc2014@aimgroup.eu

[www.sscworldcongress.org](http://www.sscworldcongress.org)